KR20150100596A - Anti-wrinkle cosmetic composition using Lactobacillus paracasei MK1 and preparation method thereof - Google Patents
Anti-wrinkle cosmetic composition using Lactobacillus paracasei MK1 and preparation method thereof Download PDFInfo
- Publication number
- KR20150100596A KR20150100596A KR1020150115383A KR20150115383A KR20150100596A KR 20150100596 A KR20150100596 A KR 20150100596A KR 1020150115383 A KR1020150115383 A KR 1020150115383A KR 20150115383 A KR20150115383 A KR 20150115383A KR 20150100596 A KR20150100596 A KR 20150100596A
- Authority
- KR
- South Korea
- Prior art keywords
- hydrolyzate
- fermented
- soybean
- soymilk
- kda
- Prior art date
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 239000002537 cosmetic Substances 0.000 title claims abstract description 33
- 230000001153 anti-wrinkle effect Effects 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title description 7
- 235000013322 soy milk Nutrition 0.000 claims abstract description 140
- 230000000694 effects Effects 0.000 claims abstract description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 32
- 231100000419 toxicity Toxicity 0.000 claims abstract description 4
- 230000001988 toxicity Effects 0.000 claims abstract description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 42
- 244000068988 Glycine max Species 0.000 claims description 41
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 238000000855 fermentation Methods 0.000 claims description 28
- 230000004151 fermentation Effects 0.000 claims description 28
- 108091005804 Peptidases Proteins 0.000 claims description 26
- 235000013336 milk Nutrition 0.000 claims description 24
- 239000008267 milk Substances 0.000 claims description 24
- 210000004080 milk Anatomy 0.000 claims description 24
- 230000037303 wrinkles Effects 0.000 claims description 24
- 239000004365 Protease Substances 0.000 claims description 18
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 18
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 102000035195 Peptidases Human genes 0.000 claims description 8
- 239000003797 essential amino acid Substances 0.000 claims description 8
- 235000020776 essential amino acid Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 claims description 5
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims 2
- 239000003549 soybean oil Substances 0.000 claims 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229940017800 lactobacillus casei Drugs 0.000 claims 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 5
- 210000004927 skin cell Anatomy 0.000 abstract description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 38
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 21
- 239000007787 solid Substances 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 239000004310 lactic acid Substances 0.000 description 17
- 235000014655 lactic acid Nutrition 0.000 description 17
- 108010035532 Collagen Proteins 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 16
- 229920001436 collagen Polymers 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
- 238000000108 ultra-filtration Methods 0.000 description 12
- 108010007119 flavourzyme Proteins 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 108010050808 Procollagen Proteins 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 108010041102 azocasein Proteins 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 235000021109 kimchi Nutrition 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 101150103556 cmk2 gene Proteins 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 101150017073 cmk1 gene Proteins 0.000 description 4
- -1 for example Substances 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 235000019750 Crude protein Nutrition 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000001967 plate count agar Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229940089837 amygdalin Drugs 0.000 description 2
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- 229940093496 esculin Drugs 0.000 description 2
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 2
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229960002413 ferric citrate Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 238000012510 peptide mapping method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- OJDZKIIKLJJBRX-NANGHANQSA-N (2S,3R,4R,5S)-2,3,4,5-tetrahydroxyhexanal (2R,3S,4S,5R)-2,3,4,5-tetrahydroxyhexanal Chemical compound C[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O.C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O OJDZKIIKLJJBRX-NANGHANQSA-N 0.000 description 1
- CDVZCUKHEYPEQS-FALJYIPSSA-N (2S,3R,4S)-2,3,4,5-tetrahydroxypentanal (2R,3S,4R)-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C=O.OC[C@@H](O)[C@H](O)[C@@H](O)C=O CDVZCUKHEYPEQS-FALJYIPSSA-N 0.000 description 1
- CDVZCUKHEYPEQS-KPXKHRLBSA-N (2s,3r,4r)-2,3,4,5-tetrahydroxypentanal;(2r,3s,4s)-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C=O CDVZCUKHEYPEQS-KPXKHRLBSA-N 0.000 description 1
- BWSWZBCSFZAYOB-CABCVRRESA-N (2s,4r)-1-dodecanoyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1C(O)=O BWSWZBCSFZAYOB-CABCVRRESA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- VBUYCZFBVCCYFD-JJYYJPOSSA-N 2-dehydro-D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-JJYYJPOSSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- RPUFVEIOVYTORQ-UOFHDTJTSA-N C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O.OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O.OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO RPUFVEIOVYTORQ-UOFHDTJTSA-N 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N D-Cellobiose Natural products OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- HEBKCHPVOIAQTA-IMJSIDKUSA-N L-arabinitol Chemical compound OC[C@H](O)C(O)[C@@H](O)CO HEBKCHPVOIAQTA-IMJSIDKUSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001468192 Leuconostoc citreum Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 108010083391 glycinin Proteins 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- DLRVVLDZNNYCBX-ABXHMFFYSA-N melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-ABXHMFFYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- ZBDGHWFPLXXWRD-JGWLITMVSA-N methyl beta-D-xylopyranoside Chemical compound CO[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O ZBDGHWFPLXXWRD-JGWLITMVSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- GSFHMOMWXNDPMM-YMDUGQBDSA-M potassium;(2r,3s,4s)-2,3,4,6-tetrahydroxy-5-oxohexanoate Chemical compound [K+].OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O GSFHMOMWXNDPMM-YMDUGQBDSA-M 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A23L1/015—
-
- A23L1/2008—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A23Y2220/17—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Beans For Foods Or Fodder (AREA)
Abstract
Description
본 발명은 주름개선용 화장료 조성물, 그 제조방법 및 그 제조방법에 이용되는 유산균에 관한 것이다.
The present invention relates to a cosmetic composition for improving wrinkles, a manufacturing method thereof, and a lactic acid bacteria used in the manufacturing method.
세포 외 기질(extracellular matrix)의 주요 구성성분인 콜라겐은 피부의 섬유아세포에서 생성되는 주요 기질 단백질로서 세포 외 간질에 존재한다. 또한, 생체 단백질 총 중량의 약 30 %를 차지하는 중요한 단백질로서 견고한 3 중 나선구조를 가지고 있다. 콜라겐은 피부, 건(tendon), 뼈 및 치아의 유기물질의 대부분을 형성하는데, 특히 뼈와 피부(지피)에 그 포함량이 높다. 대부분의 다른 체 구조물에서는 섬유상 봉입체로서 존재한다. Collagen, a major component of the extracellular matrix, is a major matrix protein produced by fibroblasts in the skin and is present in the extracellular matrix. In addition, it is an important protein that accounts for about 30% of the total weight of the biological protein and has a solid triple helix structure. Collagen forms most of the organic substances in skin, tendons, bones and teeth, especially in bones and skin (ground skin). In most other sieve structures, it is present as a fibrous inclusion body.
콜라겐은 비교적 약한 면역원인데, 콜라겐의 나선구조에 의한 잠재성 항원 결정인자의 차폐가 그 일부 원인이고, 이 나선구조는 또한 콜라겐이 단백질 분해에 대한 내성을 갖도록 한다. 콜라겐의 주된 기능으로는 피부의 기계적 견고성, 결합조직의 저향력과 조직의 결합력, 세포 접착의 지탱, 세포 분할과 분화(유기체의 성장 혹은 상처 치유시)의 유도 등이 알려져 있다(Van der Rest 등, Ann NY Acad Sci, 1990). Collagen is a relatively weak immunogen, partly due to the shielding of latent antigenic determinants by the helix structure of collagen, which also makes collagen resistant to protein degradation. The main functions of collagen are known for its mechanical firmness, connective tissue resistance and tissue bonding, support for cell adhesion, and induction of cell division and differentiation (in case of growth of organisms or wound healing) (Van der Rest, etc.). , Ann NY Acad Sci, 1990).
이러한 콜라겐은 연령 및 자외선 조사에 의한 광노화에 의해 감소하며, 이는 피부의 주름 형성과 밀접한 연관이 있다고 알려져 있다(Arthur K. Balin et al., Aging and the skin, 1989). 또한 콜라겐은 상처치유에 있어서 중요한 역할을 담당하며, 손상된 상피에서 콜라겐의 합성을 촉진시켜서 상처를 신속하고 흉터 없이 회복시킬 수 있다. This collagen is reduced by age and photoaging caused by UV irradiation, and it is known that it is closely related to the formation of wrinkles in the skin (Arthur K. Balin et al., Aging and the skin, 1989). In addition, collagen plays an important role in wound healing, and by promoting the synthesis of collagen in the damaged epithelium, wounds can be recovered quickly and without scarring.
종래에는 콜라겐의 피부 보습 효과 및 상처 치유 효과를 이용하기 위하여 화장품 또는 연고 등과 같은 피부외용제 조성물에 콜라겐을 배합한 제품들이 출시되어 있으나, 이들 제품들은 콜라겐 자체를 피부 표면에 도포하는 것으로서 고분자 물질인 콜라겐의 경피 흡수가 어려워 보습작용 또는 상처치유 효과를 기대할 수 없으므로 본질적인 피부기능 개선 및 상처치유의 기능을 나타낸다고 말할 수 없었다. Conventionally, in order to take advantage of the skin moisturizing effect and wound healing effect of collagen, products containing collagen in external skin preparations such as cosmetics or ointments have been released. However, these products apply collagen itself to the skin surface, and are a polymer substance called collagen. It could not be said that it shows essential skin function improvement and wound healing function because it cannot be expected to have a moisturizing effect or wound healing effect due to its difficulty in transdermal absorption.
한국등록특허 제0987518호는 대두추출물 및 엽산을 포함하는 배지에 바실러스 서브틸리스를 접종하여 통성혐기적 조건에서 발효시키고, 발효 후 분자량 500 kDa 이하의 물질을 제거하여 제조된 고분자물질을 유효성분으로 포함하는 콜라겐 생합성 촉진 효과를 갖는 화장료 조성물을 개시하고 있고, 한국 공개특허 제2010-0020124호는 단일 균주에 의한 콩 발효물에 비해 비타민과 영양성분이 뛰어난 복합 김치유산균에 의한 콩 발효물을 유효성분으로 하는 주름개선에 효과적인 화장료 조성물을 개시하고 있으며, 한국 공개특허 제2011-0041178호는 발아콩과 깨의 혼합물을 백국균, 황국균, 고초균 등으로 발효시킨 발효물을 유효성분으로 하는 주름개선에 효과적인 화장료 조성물을 개시하고 있다. Korean Patent Registration No. 0987518 uses a high molecular weight prepared by inoculating Bacillus subtilis in a medium containing soybean extract and folic acid, fermenting it under aerobic anaerobic conditions, and removing substances with a molecular weight of 500 kDa or less after fermentation. It discloses a cosmetic composition having an effect of promoting collagen biosynthesis including, and Korean Patent Laid-Open No. 2010-0020124 is an active ingredient of soybean fermented product by complex kimchi lactic acid bacteria superior in vitamins and nutrients compared to soybean fermented product by a single strain. A cosmetic composition effective for improving wrinkles is disclosed, and Korean Patent Laid-Open No. 2011-0041178 is effective in improving wrinkles using a fermented product fermented with a mixture of germinated soybeans and sesame seeds, such as Baekguk, Hwangguk, and Bacillus. Disclosed is a cosmetic composition.
그러나 저분자량의 대두 펩타이드 또는 그를 함유하는 분획물의 주름개선 효과에 대해서는 보고된 바 없다.
However, there has been no report on the anti-wrinkle effect of a low molecular weight soybean peptide or a fraction containing the same.
본 발명은 주름개선용 화장료 조성물의 유효성분으로 사용할 수 있는 I형 프로콜라겐 생성 활성 및 종양괴사인자-알파(TNF-α) 억제 활성을 동시에 갖는 두유발효물 또는 그로부터 제조된 두유 펩타이드 분획물, 그 두유 펩타이드 분획물의 제조방법, 및 그 제조방법에 이용되는 신규 유산균을 제공하는 것을 목적으로 한다.
The present invention is a soybean fermented product having both type I procollagen production activity and tumor necrosis factor-alpha (TNF-α) inhibitory activity that can be used as an active ingredient in a cosmetic composition for improving wrinkles, or a soymilk peptide fraction prepared therefrom, and soy milk An object of the present invention is to provide a method for preparing a peptide fraction, and a novel lactic acid bacteria used in the method for preparing the same.
본 발명은 상기 과제해결을 위하여, 두유에 락토바실러스 파라카제이(Lactobacillus paracasei) MK1 [기탁번호: KFCC11552P]를 접종하여 발효시킨 두유 발효물을 유효성분으로 하는 주름개선용 화장료 조성물을 제공한다.In order to solve the above problems, the present invention provides a cosmetic composition for improving wrinkles comprising fermented soymilk fermented by inoculating soymilk with Lactobacillus paracasei MK1 [Accession No.: KFCC11552P] as an active ingredient.
본 발명의 주름개선용 화장료 조성물은, 상기 두유를 단백분해효소로 가수분해한 두유 가수분해물에 락토바실러스 파라카제이(Lactobacillus paracasei) MK1 [기탁번호: KFCC11552P]를 접종하여 발효시킨 두유 가수분해물의 발효물; 또는 상기 두유에 락토바실러스 파라카제이(Lactobacillus paracasei) MK1 [기탁번호: KFCC11552P]를 접종하여 발효시킨 두유 발효물을 단백분해효소로 가수분해한 두유 발효물의 가수분해물;을 유효성분으로 하는 것이 바람직하다.The cosmetic composition for wrinkle improvement of the present invention is fermented by inoculating the soymilk hydrolyzate obtained by hydrolyzing the soymilk with a proteolytic enzyme with Lactobacillus paracasei MK1 [Accession Number: KFCC11552P] water; Alternatively, the soymilk fermented product obtained by inoculating Lactobacillus paracasei MK1 [Accession No.: KFCC11552P] to the soymilk is hydrolyzed with a proteolytic enzyme; it is preferable to use as an active ingredient. .
본 발명의 주름개선용 화장료 조성물에서, 상기 단백분해효소는 후라보자임(flavourzyme)인 것이 바람직하다. In the cosmetic composition for improving wrinkles of the present invention, the proteolytic enzyme is preferably flabozyme.
본 발명의 주름개선용 화장료 조성물에서, 상기 두유 발효물은 두유 원액의 고형분 량이 25 내지 50 중량%가 되도록 희석한 두유 희석액을 발효시킨 두유 발효물이 바람직하다. In the cosmetic composition for improving wrinkles of the present invention, the fermented soybean milk is preferably a fermented soymilk fermented product obtained by fermenting a dilute soymilk diluted so that the solid content of the soymilk stock solution is 25 to 50% by weight.
본 발명의 주름개선용 화장료 조성물은, 상기 두유 발효물, 두유 가수분해물의 발효물 또는 두유 발효물의 가수분해물에서, 분자량 30 kDa 초과하는 단백질 또는 펩타이드를 제거한 두유 펩타이드 분획물을 유효성분으로 하는 것이 바람직하다. In the cosmetic composition for improving wrinkles of the present invention, it is preferable that the soymilk peptide fraction from which the protein or peptide having a molecular weight exceeding 30 kDa is removed from the fermented soybean milk, the fermented product of the soymilk hydrolyzate, or the hydrolyzate of the fermented soybean milk as an active ingredient .
본 발명의 주름개선용 화장료 조성물은, 상기 두유 발효물, 두유 가수분해물의 발효물 또는 두유 발효물의 가수분해물에서 분자량 5 kDa 초과하는 단백질 또는 펩타이드를 제거한 두유 펩타이드 분획물을 유효성분으로 하는 것이 바람직하다. In the cosmetic composition for improving wrinkles of the present invention, the soymilk peptide fraction from which proteins or peptides having a molecular weight exceeding 5 kDa are removed from the fermented soybean milk, the fermented soymilk hydrolyzate, or the hydrolyzate of the soymilk fermented product is preferably used as an active ingredient.
본 발명의 주름개선용 화장료 조성물에서, 상기 분획물은 I형 프로콜라겐 생성 활성 및 종양괴사인자-알파(TNF-α) 억제 활성을 갖는 것이 바람직하다. In the cosmetic composition for improving wrinkles of the present invention, the fraction preferably has type I procollagen production activity and tumor necrosis factor-alpha (TNF-α) inhibitory activity.
본 발명의 주름개선용 화장료 조성물에서, 상기 분획물은 인간 진피 섬유아세포 및 인간 각질세포에 독성을 나타내지 않는 것이 바람직하다. In the cosmetic composition for improving wrinkles of the present invention, the fraction is preferably not toxic to human dermal fibroblasts and human keratinocytes.
본 발명의 주름개선용 화장료 조성물에서, 상기 분획물은 전체 분획물에서 유리아미노산 함량이 60 mg% 이상이고, 상기 유리아미노산 중에서 필수아미노산 함량이 50 중량% 이상인 것이 바람직하다. In the cosmetic composition for improving wrinkles of the present invention, it is preferable that the fraction has a free amino acid content of 60 mg% or more in the total fraction, and an essential amino acid content of 50 wt% or more in the free amino acid.
본 발명의 주름개선용 화장료 조성물에서, 상기 분획물은 서열번호 1의 아미노산 서열을 가지는 펩타이드를 포함하는 것이 바람직하다. In the cosmetic composition for improving wrinkles of the present invention, it is preferable that the fraction comprises a peptide having an amino acid sequence of SEQ ID NO: 1.
또한 본 발명은 두유를 단백분해효소인 후라보자임(flavourzyme)으로 가수분해하는 두유 가수분해물 제조단계; 상기 두유 가수분해물에 락토바실러스 파라카제이(Lactobacillus paracasei) MK1 [기탁번호: KFCC11552P]를 접종하여 발효시키는 두유 가수분해물의 발효물 제조단계; 및 상기 두유 가수분해물의 발효물에서 분자량 5 kDa 초과하는 단백질 또는 펩타이드를 제거하여 두유 펩타이드 분획물을 얻는 단계;를 포함하는 주름개선용 두유 펩타이드 분획물의 제조방법을 제공한다.In addition, the present invention is a soybean milk hydrolyzate preparation step of hydrolyzing soymilk with a proteolytic enzyme, flavozyme; Fermentation step of fermenting soy milk hydrolyzate by inoculating and fermenting Lactobacillus paracasei MK1 [Accession No.: KFCC11552P] to the soy milk hydrolyzate; And removing a protein or peptide having a molecular weight of more than 5 kDa from the fermented product of the soymilk hydrolyzate to obtain a soymilk peptide fraction.
또한 본 발명은 두유에 락토바실러스 파라카제이(Lactobacillus paracasei) MK1 [기탁번호: KFCC11552P]를 접종하여 발효시키는 두유 발효물 제조단계; 상기 두유 발효물을 단백분해효소인 후라보자임(flavourzyme)으로 가수분해하는 두유 발효물의 가수분해물 제조단계; 및 상기 두유 발효물의 가수분해물에서 분자량 5 kDa 초과하는 단백질 또는 펩타이드를 제거하여 두유 펩타이드 분획물을 얻는 단계;를 포함하는 주름개선용 두유 펩타이드 분획물의 제조방법을 제공한다.In addition, the present invention is a soybean milk fermentation production step of inoculating and fermenting Lactobacillus paracasei MK1 [accession number: KFCC11552P] in soymilk; A step of preparing a hydrolyzate of fermented soybean milk by hydrolyzing the fermented soybean milk with flavozyme, a proteolytic enzyme; And it provides a method for preparing a soymilk peptide fraction for wrinkle improvement comprising a; and removing a protein or peptide having a molecular weight of more than 5 kDa from the hydrolyzate of the fermented soybean milk to obtain a soymilk peptide fraction.
또한 본 발명은 두유를 발효시켜 I형 프로콜라겐 생성 활성 및 종양괴사인자-알파(TNF-α) 억제 활성을 갖는 두유 펩타이드를 생성하는 락토바실러스 파라카제이(Lactobacillus paracasei) MK1 [기탁번호: KFCC11552P]를 제공한다.In addition, the present invention fermented soymilk to produce a soymilk peptide having type I procollagen production activity and tumor necrosis factor-alpha (TNF-α) inhibitory activity Lactobacillus paracasei (Lactobacillus paracasei) MK1 [Accession No: KFCC11552P] Provides.
본 발명의 주름개선용 화장료 조성물은 조성물 총 중량에 대하여 상기 두유 발효물을 0.00001 내지 50% 중량%, 바람직하게는, 0.0001 내지 20% 중량%, 보다 바람직하게는 0.1 내지 10% 중량%으로 포함한다. 그러나 상기와 같은 조성은 반드시 이에 한정되는 것은 아니고, 환자의 상태 및 진행 정도에 따라 변할 수 있다. The cosmetic composition for improving wrinkles of the present invention comprises 0.00001 to 50% by weight of the fermented soybean milk in an amount of 0.00001 to 50% by weight, preferably, 0.0001 to 20% by weight, more preferably 0.1 to 10% by weight, based on the total weight of the composition. . However, the composition as described above is not necessarily limited thereto, and may vary depending on the patient's condition and progression.
본 발명의 화장료 조성물에 포함되는 성분은 유효성분으로서 상기 두유 발효물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예를 들면, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제 및 담체를 포함한다. Ingredients included in the cosmetic composition of the present invention may include ingredients commonly used in cosmetic compositions in addition to the fermented soybean milk as an active ingredient, for example, stabilizers, solubilizers, vitamins, pigments, and flavors. Phosphorus adjuvants and carriers.
본 발명의 화장료 조성물의 제형은 특별히 제한되지 않으며, 목적하는 바에 따라 적절히 선택할 수 있다. 예를 들어, 본 발명의 화장료 조성물은 피부외용 연고, 로션, 유연화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 팩, 에멀젼, 오일젤 등의 제형으로 제조될 수 있다.
The formulation of the cosmetic composition of the present invention is not particularly limited, and may be appropriately selected depending on the intended purpose. For example, the cosmetic composition of the present invention may be prepared in a formulation such as an ointment for external use of the skin, a lotion, a soft lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, a pack, an emulsion, an oil gel, and the like.
본 발명의 신규 유산균은 두유를 발효시켜 I형 프로콜라겐 생성 활성 및 종양괴사인자-알파(TNF-α) 억제 활성을 동시에 가지는 두유 펩타이드를 생성하고, 그 유산균을 이용해 제조된 두유 발효물 또는 두유 펩타이드 분획물은 피부 세포에 독성을 나타내지 않으면서 주름개선 활성을 나타내는 천연 기능성 소재로서 주름개선용 화장료 조성물의 소재로 활용할 수 있다.
The novel lactic acid bacteria of the present invention ferment soy milk to produce a soymilk peptide having both type I procollagen production activity and tumor necrosis factor-alpha (TNF-α) inhibitory activity, and a soymilk fermented product or soymilk peptide prepared using the lactic acid bacteria The fraction is a natural functional material that exhibits anti-wrinkle activity without showing toxicity to skin cells, and can be used as a material for a cosmetic composition for improving wrinkles.
도 1a 내지 도 1d는 실험예 3에서 SDS-PAGE에 따른 단백질 밴드 패턴을 나타낸 것으로, 도 1a 내지 도 1d에서 공통적으로 M은 분자량 마커를, C는 두유를 나타내고, 도 1a에서 1. GK1; 2. GK2; 3. GK3; 4. GK4; 5. GK5; 6. OJ1; 7. OJ2를 나타내며, 도 1b에서 1. CRJ; 2. JJ; 3. CMK2; 4. K1; 5. CCK; 6. MK1을 나타내며, 도 1c에서 1. SULK 2. radish 3. K2; 4. kimchis; 5. GOM를 나타내고, 도 1d에서 1. NJ3; 2. NJ1; 3. SJ; 4. CMK1를 나타낸다.
도 2는 MK1 균주의 형태를 전자주사현미경으로 30,000배 확대한 사진이다.
도 3은 MK1 균주의 필로제닉 트리를 나타낸 것이다.
도 4a 내지 도 4c는 실험예 5의 1)에서 배양온도 및 시간에 따른 적정산도, pH 및 균수를 각각 나타낸 그래프이다.
도 5a 및 도 5b는 실험예 5의 1)에서 배양온도에 따른 배양 상등액의 SDS-PAGE 단백질 밴드 패턴을 나타낸 것으로, 공통적으로 M은 분자량 마커를, 도 5a에서 1. 25℃, 0 hr; 2. 25℃, 16 hr; 3. 25℃, 24 hr; 4. 30℃, 0 time; 5. 30℃, 16 hr; 6. 30℃, 24 hr을 나타내고, 도 5b에서 1. 37℃, 0 hr; 2. 37℃, 16 hr; 3. 37℃, 24 hr; 4. 40℃, 0 hr; 5. 40℃, 16 hr; 6. 40℃, 24 hr를 나타낸다.
도 6a 내지 도 6c는 실험예 5의 2)에서 희석농도 및 시간에 따른 적정산도, pH 및 균수를 각각 나타낸 그래프이다.
도 7a 내지 도 7d는 실험예 5의 2)에서 희석농도에 따라 각각 100%, 75%, 50% 및 25% 두유의 배양 상등액의 SDS-PAGE 단백질 밴드 패턴을 나타낸 것으로, 공통적으로 M은 분자량 마커를, 1. 0 hr; 2. 6 hr; 3. 12 hr; 4. 18 hr; 5. 24 hr의 배양시간을 나타낸다.
도 8a 내지 도 8j는 시료의 종류 및 농도에 따른 HaCaT 세포에 대한 세포독성을 확인할 수 있는 MTT분석 그래프이다.
도 9a 내지 도 9e는 I형 프로콜라겐 생성량을 측정한 그래프로서, 도 9a는 양성대조군으로 아스코르빈산 50 μM 처리한 것이고, 도 9b는 MK1 균주로 발효시키지 않은 50% 두유인 50S, 도 9c 내지 도 9e는 농도별로 50SFMKUF5, 50SMKP, 50SFMKUF30, 50SPMK 및 50SFMK를 양성 대조군인 아스코르빈산과 비교한 것이다.
도 10a 내지 도 10e는 TNF-α의 생성량을 측정한 그래프로서, 도 10a는 양성대조군으로 덱사메타손(DXMS) 1μM 처리한 것이고, 도 10b는 MK1 균주로 발효시키지 않은 50% 두유인 50S, 도 10c 내지 도 10e는 농도별로 50SFMKUF5, 50SMKP, 50SFMKUF30, 50SPMK 및 50SFMK를 양성 대조군인 덱사메타손과 비교한 것이다.
도 11a 및 도 11b는 실험예 9에서 50SFMKUF5 분획물을 LC/MS-MS를 사용하여 peptide mapping을 진행한 결과로서, 도 11a는 LC chromatogram, 도 11b는 MS chromatogram이다.1A to 1D show a protein band pattern according to SDS-PAGE in Experimental Example 3. In FIGS. 1A to 1D, M represents a molecular weight marker, C represents soy milk, and in Figure 1A 1. GK1; 2. GK2; 3. GK3; 4. GK4; 5. GK5; 6. OJ1; 7. OJ2 is shown, and in Fig. 1B, 1. CRJ; 2. JJ; 3. CMK2; 4. K1; 5. CCK; 6. MK1 is shown, and in Fig. 1c, 1.
Figure 2 is a photograph of the morphology of the MK1 strain magnified 30,000 times with an electron scanning microscope.
3 shows the phylogenic tree of the MK1 strain.
4A to 4C are graphs showing titratable acidity, pH, and number of bacteria according to culture temperature and time in 1) of Experimental Example 5, respectively.
Figures 5a and 5b show the SDS-PAGE protein band pattern of the culture supernatant according to the culture temperature in 1) of Experimental Example 5, in common M is a molecular weight marker, in
6A to 6C are graphs showing titratable acidity, pH, and number of bacteria according to dilution concentration and time in 2) of Experimental Example 5, respectively.
7A to 7D show the SDS-PAGE protein band pattern of the culture supernatant of 100%, 75%, 50%, and 25% soymilk, respectively, depending on the dilution concentration in 2) of Experimental Example 5, in common M is a molecular weight marker To, 1. 0 hr; 2. 6 hr; 3. 12 hr; 4. 18 hr; 5. Indicate the incubation time of 24 hr.
8A to 8J are graphs of MTT analysis that can confirm cytotoxicity to HaCaT cells according to the type and concentration of a sample.
9A to 9E are graphs measuring the amount of I-type procollagen production, FIG. 9A is a 50 μM treatment of ascorbic acid as a positive control, and FIG. 9B is 50S, 50% soymilk not fermented with an MK1 strain, and FIGS. 9C to Figure 9e is a comparison of 50SFMKUF5, 50SMKP, 50SFMKUF30, 50SPMK and 50SFMK by concentration with ascorbic acid as a positive control.
Figures 10a to 10e are graphs measuring the production amount of TNF-α, Figure 10a is dexamethasone (DXMS) 1 μM treatment as a positive control, Figure 10b is 50S, 50% soymilk not fermented with MK1 strain, Figures 10c to Figure 10e is a comparison of 50SFMKUF5, 50SMKP, 50SFMKUF30, 50SPMK and 50SFMK with the positive control dexamethasone by concentration.
11A and 11B are results of peptide mapping of the 50SFMKUF5 fraction using LC/MS-MS in Experimental Example 9, and FIG. 11A is an LC chromatogram, and FIG. 11B is an MS chromatogram.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명한다. 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들에 의해 제한되는 것은 아니다.
Hereinafter, the present invention will be described in more detail through examples. These examples are for explaining the present invention in more detail, and the scope of the present invention is not limited thereto.
실험재료Experimental material
두유는 (학)연세대학교우유의 것을 사용하였고, BCP plate count agar는 교쿠토제약공업회사(Japan)에서 구입하였으며, skim milk와 MRS broth 및 agar는 Difco Co.(USA)에서 구입하였다. Azo-casein과 bovine serum albumin은 Sigma-Aldrich(USA)에서 구입하여 사용하였으며, protein assay reagent는 Bio-rad사(USA)의 것을 사용하였다. API kit는 bioMerieux Ltd.(France) 제품을 이용하였다. Protamex와 flavourzyme은 Novozymes사(Denmark) 제품을 이용하였다. Procollagen type-Ⅰ C-Peptide(PIP) EIA kit는 Takara Bio사(MK101, Japan)의 제품과 TNF-α의 측정은 Invitrogen사(#KHC3012, USA)의 kit를 사용하였다.
Soymilk was obtained from Yonsei University's milk, BCP plate count agar was purchased from Kyokuto Pharmaceutical Co., Ltd. (Japan), and skim milk, MRS broth and agar were purchased from Difco Co. (USA). Azo-casein and bovine serum albumin were purchased and used from Sigma-Aldrich (USA), and a protein assay reagent was used by Bio-rad (USA). The API kit was manufactured by bioMerieux Ltd. (France). Protamex and flavorzyme were manufactured by Novozymes (Denmark). The Procollagen type-I C-Peptide (PIP) EIA kit was manufactured by Takara Bio (MK101, Japan) and TNF-α was measured by Invitrogen (#KHC3012, USA).
실험예 1: 프로테아제 활성이 높은 유산균의 1차 선별Experimental Example 1: Primary screening of lactic acid bacteria having high protease activity
두유로부터 주름개선용 저분자 펩타이드 또는 펩타이드 이외의 활성물질을 얻기 위하여 프로테아제 활성이 높은 미생물을 안전하고 생리활성면에서 뛰어난 유산균 중에서 탐색하였다. In order to obtain a low molecular weight peptide for improving wrinkles or an active substance other than a peptide from soy milk, microorganisms with high protease activity were searched among lactic acid bacteria that are safe and excellent in physiological activity.
김치, 젓갈 등의 다양한 발효식품을 구입하여 멸균생리식염수(0.88%(w/v) NaCl)에 희석한 후 그 희석액을 skim milk가 첨가된 BCP plate count agar에 도말하여 37℃에서 2일간 배양하고, colony 주변에 투명한 clear zone을 형성하는 유산균을 분리하였다. 총 180주의 유산균 중 22주의 균주에서 일정 수준 이상의 clear zone을 형성함을 확인하였다. 이들 균주들을 BCP plate count agar에 계대 배양하여 순수 분리하였다.
After purchasing various fermented foods such as kimchi and salted fish, dilute it in sterile physiological saline (0.88%(w/v) NaCl), spread the diluted solution on a BCP plate count agar added with skim milk, and incubate at 37°C for 2 days. , Lactobacillus forming a transparent clear zone around the colony was isolated. It was confirmed that out of a total of 180 lactic acid bacteria, 22 strains formed a clear zone above a certain level. These strains were subcultured in BCP plate count agar and purely isolated.
실험예 2: 프로테아제 활성, 산도 및 pH에 따른 2차 선별Experimental Example 2: Secondary screening according to protease activity, acidity and pH
상기 1차 선발된 유산균의 2차 선별을 위하여 azo-casein법을 응용하여 protease 활성을 측정하여 표 1에 나타내었다. 1차 선발된 균주들을 MRS broth에 접종하고 37℃, 48시간 배양한 후 균배양액을 16,100×g에서 5분간 원심분리하여 세포를 제거한 후 상등액을 취하여 조효소로 사용하였다. Protease 활성 측정에 사용한 기질로는 azo-casein을 사용하였고, 2 g의 azo-casein을 100 mL의 100 mM 인산완충용액(pH 7.0)에 용해한 후, azo-casein 기질용액 500 μL를 40℃, 5분간 예열하였다. 예열한 azo-casein 기질용액에 조효소 50 μL를 혼합하여 40℃에서 10분간 반응시켜 azo기를 유리시켰다. 여기에 12%(w/v) trichloroacetic acid 1 mL을 가하여 잔존활성을 실활시키고, 반응하지 않은 azo-casein은 4℃에서 30분간 침전시킨 후 16,100×g에서 10분간 원심분리하였다. 원심분리 후 상등액 500 μL를 취한 후 동량의 0.5 M NaOH 용액을 가하여 440 nm에서 흡광도를 측정하였다. 이때 효소 활성 1 unit은 주어진 조건에서 분당 440 nm에서의 흡광도를 0.001 증가시키는 양으로 정하였다. Table 1 shows the protease activity was measured by applying the azo-casein method for the second screening of the first selected lactic acid bacteria. The first selected strains were inoculated into MRS broth and cultured at 37° C. for 48 hours, and then the culture solution was centrifuged at 16,100×g for 5 minutes to remove cells, and the supernatant was taken and used as a coenzyme. Azo-casein was used as a substrate used to measure protease activity. After dissolving 2 g of azo-casein in 100 mL of 100 mM phosphate buffer solution (pH 7.0), 500 μL of azo-casein substrate solution was added at 40°C, 5 Preheated for minutes. 50 μL of the coenzyme was mixed with the preheated azo-casein substrate solution and reacted at 40° C. for 10 minutes to release the azo group. To this, 1 mL of 12% (w/v) trichloroacetic acid was added to inactivate the residual activity, and unreacted azo-casein was precipitated at 4° C. for 30 minutes and then centrifuged at 16,100×g for 10 minutes. After centrifugation, 500 μL of the supernatant was taken, and the same amount of 0.5 M NaOH solution was added to measure the absorbance at 440 nm. At this time, 1 unit of enzyme activity was set as an amount to increase the absorbance at 440 nm per minute by 0.001 under the given conditions.
GK2
GK3
GK4
GK5
GOM
K1
K2
NJ1
NJ2
NJ3
MK1
SJ
BK
SULK
OJ1
OJ2
JJ
CRJ
CCK
CMK1
CMK2GK1
GK2
GK3
GK4
GK5
GOM
K1
K2
NJ1
NJ2
NJ3
MK1
SJ
BK
SULK
OJ1
OJ2
JJ
CRJ
CCK
CMK1
CMK2
71
164
98
77
114
2
73
134
96
118
126
128
138
112
120
168
130
116
116
102
152140
71
164
98
77
114
2
73
134
96
118
126
128
138
112
120
168
130
116
116
102
152
Min 등(Min SG, Kim JH, Kim TW, Kim KN. Isolation and identification of protease producing bacteria in kimchi. Korean J. Food Sci. Technol. 35: 660-670 (2003))의 연구에서 김치에서 분리한 protease를 생성하는 균주를 분리 및 동정하였는데, Lactobacillus delbruekii로 동정된 균주는 58 mU/mg, 다른 유산균주인 Leuconostoc citreum의 protease 활성은 5 mU/mg으로 확인되었다.Protease isolated from kimchi in a study by Min et al. (Min SG, Kim JH, Kim TW, Kim KN. Isolation and identification of protease producing bacteria in kimchi. Korean J. Food Sci. Technol. 35: 660-670 (2003)) Was isolated and identified. The strain identified as Lactobacillus delbruekii was 58 mU/mg, and the protease activity of Leuconostoc citreum , another lactic acid strain, was 5 mU/mg.
그러나 표 1에 나타낸 바와 같이 실험예 1에서 선별된 22주의 균주는 높은 프로테아제 활성을 나타내었다. 가장 높은 protease 활성을 나타낸 균주는 OJ1이 168 mU/mL·min으로 protease 활성이 높게 측정되었고, 그 다음으로 GK3, CMK2, GK1(각 164, 152, 140 mU/mL·min)의 순서로 측정되었다. 또한 가장 낮은 활성을 나타낸 K1는 2 mU/mL·min으로 같은 분리원(영문약어를 동일하게 표시)에서 분리된 균주라도 protease의 활성이 각기 다른 것을 확인할 수 있었다.
However, as shown in Table 1, the strains of 22 strains selected in Experimental Example 1 exhibited high protease activity. In the strain showing the highest protease activity, OJ1 was measured to have high protease activity at 168 mU/mL·min, followed by GK3, CMK2, and GK1 (each 164, 152, 140 mU/mL·min) in that order. . In addition, K1, which showed the lowest activity, was 2 mU/mL·min, and it was confirmed that even the strains isolated from the same source (English abbreviations are indicated identically) have different protease activities.
또한 상기 실험예 1에서 선별된 22주의 균주를 121℃에서 15분간 멸균한 두유를 배지로 사용하여 37℃에서 48시간 배양한 후, 적정 산도와 pH를 측정하여 각각 표 2에 나타내고, 두유에서의 유산균의 성장 및 발효 특성을 확인하였다. 적정산도는 증류수 10 mL에 배양액을 9 mL 취하여 희석한 후, 0.1 % phenolphthalein 용액 500 μL를 첨가하고, 30초 동안 미홍색이 없어지지 않을 때까지 0.1 N NaOH로 적정하여 그 소비량을 % 적정 산도로 나타내었다. 산도는 유산(0.1N NaOH 1 mL = 유산 0.009 g)으로 나타내었고, 남은 배양액을 pH meter(FE-20K, METTLER TOREDO, USA)를 이용하여 pH를 측정하였다.
In addition, the 22 strains selected in Experimental Example 1 were cultured for 48 hours at 37°C using soymilk sterilized at 121°C for 15 minutes as a medium, and then the appropriate acidity and pH were measured and shown in Table 2, respectively. The growth and fermentation characteristics of lactic acid bacteria were confirmed. For titratable acidity, take 9 ml of the culture solution in 10 ml of distilled water, dilute it, add 500 μL of 0.1% phenolphthalein solution, and titrate with 0.1 N NaOH for 30 seconds until the pale red color does not disappear, and the consumption is expressed as% titration acidity. I got it. Acidity was expressed as lactic acid (0.1
GK2
GK3
GK4
GK5
GOM
K1
K2
NJ1
NJ2
NJ3
MK1
SJ
BK
SULK
OJ1
OJ2
JJ
CRJ
CCK
CMK1
CMK2GK1
GK2
GK3
GK4
GK5
GOM
K1
K2
NJ1
NJ2
NJ3
MK1
SJ
BK
SULK
OJ1
OJ2
JJ
CRJ
CCK
CMK1
CMK2
4.84
4.95
4.78
4.71
6.44
4.76
5.24
4.59
ND
4.60
4.10
4.58
6.55
4.90
4.61
4.65
5.05
4.64
4.38
4.82
4.675.10
4.84
4.95
4.78
4.71
6.44
4.76
5.24
4.59
ND
4.60
4.10
4.58
6.55
4.90
4.61
4.65
5.05
4.64
4.38
4.82
4.67
0.17
0.14
0.17
0.17
0.00
0.16
ND1)
0.01
ND
0.19
0.28
0.18
0.03
0.13
0.18
0.18
0.11
0.17
0.19
0.16
0.180.11
0.17
0.14
0.17
0.17
0.00
0.16
ND 1)
0.01
ND
0.19
0.28
0.18
0.03
0.13
0.18
0.18
0.11
0.17
0.19
0.16
0.18
1)ND는 Not detemided의 약어임 1) ND stands for Not detemided
상기 표 2에 나타낸 바와 같이 MK1의 pH는 4.10으로 가장 낮은 pH를 보였고, 0.28%의 적정 산도로 다른 균주들보다 높은 산도를 나타냈다. 반면에 BK 균주를 접종하여 발효한 두유는 pH가 6.55로 유산균의 산생성이 전혀 이루어지지 않았고, 적정산도 또한 0.03% 밖에 측정되지 않았다. 이는 BK 균주가 두유에서는 거의 생장이 불가하다고 추정할 수 있었다.
As shown in Table 2, the pH of MK1 showed the lowest pH of 4.10, and showed a higher acidity than other strains with an appropriate acidity of 0.28%. On the other hand, the soymilk fermented by inoculating the BK strain had a pH of 6.55, so that acid production of lactic acid bacteria did not occur at all, and titratable acidity was also measured at only 0.03%. This could be estimated that the BK strain was almost impossible to grow in soy milk.
실험예 3: 단백질 정량 및 SDS-PAGE 패턴을 이용한 3차 선별Experimental Example 3: Protein quantification and third screening using SDS-PAGE pattern
상기 1차 선발된 유산균의 3차 선별을 위하여 실험예 2에서 121℃에서 15분간 멸균한 두유를 배지로 사용하여 37℃에서 48시간 배양한 배양액을 16,100×g에서 5분간 원심분리하여 세포를 제거한 후 상등액을 취하여 Bio-rad사의 protein assay reagent를 사용하하여 단백질을 정량하여 표 3에 나타내었다(Bradford, 1976). For the third screening of the first selected lactic acid bacteria, cells were removed by centrifugation at 16,100×g for 5 minutes using soymilk sterilized at 121°C for 15 minutes as a medium in Experimental Example 2 and cultured for 48 hours at 37°C. After taking the supernatant, the protein was quantified using Bio-rad's protein assay reagent, and it is shown in Table 3 (Bradford, 1976).
GK2
GK3
GK4
GK5
GOM
K1
K2
NJ1
NJ2
NJ3
MK1
SJ
BK
SULK
OJ1
OJ2
JJ
CRJ
CCK
CMK1
CMK2GK1
GK2
GK3
GK4
GK5
GOM
K1
K2
NJ1
NJ2
NJ3
MK1
SJ
BK
SULK
OJ1
OJ2
JJ
CRJ
CCK
CMK1
CMK2
1.08
1.04
0.99
1.08
16.90
1.10
1.24
1.10
ND1)
1.20
0.74
1.10
ND
1.10
1.11
1.17
1.18
0.90
1.15
1.40
1.121.10
1.08
1.04
0.99
1.08
16.90
1.10
1.24
1.10
ND 1)
1.20
0.74
1.10
ND
1.10
1.11
1.17
1.18
0.90
1.15
1.40
1.12
1)ND는 Not detemided의 약어임 1) ND stands for Not detemided
MK1은 pH와 적정산도의 결과에서 가장 좋은 결과를 나타내었고, bradford assay를 이용한 단백질의 측정결과, 0.74 μg/μL로 낮은 수치의 단백질 양을 측정할 수 있었다. MK1과 반대로 GOM 균주의 경우 pH와 적정 산도의 결과에서도 볼 수 있듯이 단백질 양이 16.90 μg/μL으로 측정되어 가장 높은 단백질 양을 관찰할 수 있었다. 이는 두유 내에 존재하던 단백질이 균주들에 의하여 분해되었거나 혹은 그렇지 않은 것을 단적으로 보여주는 결과라고 판단할 수 있다. MK1 showed the best results in the results of pH and titratable acidity, and as a result of protein measurement using the bradford assay, it was possible to measure the amount of protein as low as 0.74 μg/μL. In contrast to MK1, in the case of the GOM strain, the protein amount was measured as 16.90 μg/μL, as can be seen from the results of pH and titration acidity, and the highest protein amount could be observed. This can be judged as a result showing that the protein present in the soymilk has been degraded or not degraded by the strains.
또한 상기 원심분리하여 세포를 제거한 후 상등액을 SDS-PAGE에 시료의 농도가 10 μg/μL가 되게 loading하여 전기영동을 실시한 후 SDS-PAGE상의 단백질 밴드 패턴을 확인하여 그 결과를 도 1a 내지 도 1d에 나타내었다. In addition, after removing the cells by centrifugation, the supernatant was loaded on SDS-PAGE so that the concentration of the sample was 10 μg/μL, subjected to electrophoresis, and then the protein band pattern on the SDS-PAGE was confirmed, and the results are shown in FIGS. 1A to 1D. Shown in.
두유를 MK1으로 발효시켰을 경우 수많은 major band가 14.3 kDa 부근에 존재하는 것을 확인할 수 있었다. 이는 두유 내에 존재하는 단백질이 가수분해되어 주요 밴드들이 사라지는 패턴으로 단백질 가수분해활성의 정도를 알 수 있었다. When soymilk was fermented with MK1, it could be confirmed that numerous major bands exist around 14.3 kDa. This is a pattern in which proteins present in soy milk are hydrolyzed and major bands disappear, indicating the degree of proteolytic activity.
이상의 실험예 1 내지 3의 protease 활성, pH와 적정산도 및 SDS-PAGE의 pattern을 결과를 종합하여 두유를 발효하여 protease 활성으로 두유 내 단백질을 가수분해하여 주름개선 활성을 가지는 저분자 펩타이드 생성 균주 후보로 MK1 균주를 선정하였다.
By synthesizing the results of the protease activity, pH, titratable acidity and SDS-PAGE pattern of Experimental Examples 1 to 3 above, fermentation of soy milk was performed to hydrolyze the protein in soy milk with protease activity to be a candidate for a strain for producing a low-molecular peptide having anti-wrinkle activity. The MK1 strain was selected.
실험예 4: MK1 균주의 동정Experimental Example 4: Identification of MK1 strain
1) 형태학적 관찰1) Morphological observation
상기 MK1 균주를 주사전자현미경(scanning electron microscope, SEM)을 이용하여 형태를 관찰한 결과, 간균으로 균체의 길이는 약 0.5×1-1.5 μm로 측정되었다.
As a result of observing the morphology of the MK1 strain using a scanning electron microscope (SEM), the length of the bacterial body as a bacillus was measured to be about 0.5×1-1.5 μm.
2) 유산균의 당대사능 확인2) Confirmation of sugar metabolism of lactic acid bacteria
상기 MK1 균주의 당대사능을 API 50 CHL system(BioMerieux, Marcy, IEtoile, France)을 이용하여 조사하여 표 4에 나타내었다.
The glucose metabolism of the MK1 strain was investigated using the
Erythritol
D-Arabinose
L-Arabinose
D-Ribose
D-Xylose
L-Xylose
D-Adonitol
Methyl-β-D-xylopyranoside
D-Galactose
D-Glucose
D-Fructose
D-Mannose
L-Sorbose
L-Rhamnose
Dulcitol
Inositol
D-Mannitol
D-Sorbitol
Methyl-α-D-mannopyranoside
Methyl-α-D-glucopyranoside
N-Acetyl glucosamine
Amygdalin
Arbutin
Esculin ferric citrateGlycerol
Erythritol
D-Arabinose
L-Arabinose
D-Ribose
D-Xylose
L-Xylose
D-Adonitol
Methyl-β-D-xylopyranoside
D-Galactose
D-Glucose
D-Fructose
D-Mannose
L-Sorbose
L-Rhamnose
Dulcitol
Inositol
D-Mannitol
D-Sorbitol
Methyl-α-D-mannopyranoside
Methyl-α-D-glucopyranoside
N-Acetyl glucosamine
Amygdalin
Arbutin
Esculin ferric citrate
-
-
-
+
-
-
-
-
+
+
+
+
-
-
-
-
+
-
-
-
+
+
+
+-
-
-
-
+
-
-
-
-
+
+
+
+
-
-
-
-
+
-
-
-
+
+
+
+
D-Cellobiose
D-Maltose
D-Lactose (bovine origin)
D-Melibiose
D-Saccharose (sucrose)
D-Trehalose
Inulin
D-Melezitose
D-Raffinose
Amidon (starch)
Glycogen
Xylitol
Gentiobiose
D-Turanose
D-Lyxose
D-Tagatose
D-Fucose
L-Fucose
D-Arabitol
L-Arabitol
Potassium Gluconate
Potassium 2-ketogluconate
Potassium 5-ketogluconate
Salicin
D-Cellobiose
D-Maltose
D-Lactose (bovine origin)
D-Melibiose
D-Saccharose (sucrose)
D-Trehalose
Inulin
D-Melezitose
D-Raffinose
Amidon (starch)
Glycogen
Xylitol
Gentiobiose
D-Turanose
D-Lyxose
D-Tagatose
D-Fucose
L-Fucose
D-Arabitol
L-Arabitol
Potassium Gluconate
Potassium 2-ketogluconate
Potassium 5-ketogluconate
-
-
-
-
+
+
+
+
-
-
-
-
-
+
-
+
-
-
-
-
-
-
-
-
-
-
-
-
+
+
+
+
-
-
-
-
-
+
-
+
-
-
-
-
-
-
-
표 4에 나타낸 것과 같이, 단당류인 glucose, galactose, fructose, ribose, maanose, tagatose와 이당류인 saccharose, trehalose, turanose를 이용하고, 다당류인 inulin과 melezitose, 당알코올인 mannitol, cyan 배당체인 amygdalin, arbutin과 raffinose 배당체인 N-acetyl glucosamin, esculin ferric citrate를 이용하는 것을 확인할 수 있었다.
As shown in Table 4, monosaccharides glucose, galactose, fructose, ribose, maanose, tagatose and disaccharides saccharose, trehalose, and turanose were used, and polysaccharides inulin and melezitose, sugar alcohols mannitol, cyan glycosides amygdalin, arbutin and It was confirmed that raffinose glycosides, N-acetyl glucosamin, and esculin ferric citrate, were used.
3) 분자생물학적 동정3) Molecular biological identification
최종적인 동정을 위하여 MK1 균주의 16S rRNA 염기서열을 결정하여 NCBI(National Center for Biotechnology Information)의 blastn program을 이용하여 분석한 후 GenBank에 등록된 표준군주(type strain)와의 상동성을 비교하였다. For final identification, the 16S rRNA nucleotide sequence of the MK1 strain was determined, analyzed using the blastn program of the National Center for Biotechnology Information (NCBI), and then homology with the type strain registered in GenBank was compared.
MK1 균주의 16S rRNA 염기서열은 서열번호 1에 나타내었고, 이 염기서열을 NCBI에서 BLASTN 프로그램을 이용하여 GenBank의 16S rRNA 염기서열과 비교한 결과 Lactobacillus 속과 높은 상동성을 나타내었고, Clustal X와 Mega 5 프로그램을 이용하여 각 Lacobacillus 유전자에 속하는 다양한 종들과 염기서열의 상동성을 비교분석하여 phylogenetic tree를 작성하여 도 3에 나타내었다.The 16S rRNA nucleotide sequence of the MK1 strain is shown in SEQ ID NO: 1, and as a result of comparing this nucleotide sequence with the 16S rRNA nucleotide sequence of GenBank using the BLASTN program in NCBI, it showed high homology with the genus Lactobacillus, and Clustal X and Mega Using the 5 program, a phylogenetic tree was created by comparing and analyzing the homology of base sequences with various species belonging to each Lacobacillus gene, and is shown in FIG. 3.
MK1은 김치에서 분리된 것으로 Latobacillus paracasei, L. casei와 높은 유사성을 갖고, 이 중 Latobacillus paracasei JCM813과 가장 높은 상동성을 나타내어 최종 선발된 균주는 락토바실러스 파라카제이(Lactobacillus paracasei) MK1으로 명명하여 한국미생물보존센터에 2013년 4월 4일 기탁하고, 기탁번호 KFCC11552P를 부여받았다.MK1 is isolated from kimchi and has a high similarity to Latobacillus paracasei and L. casei. Among them, it shows the highest homology with Latobacillus paracasei JCM813, so the final selected strain was named Lactobacillus paracasei MK1 and named Korea. It was deposited with the Microbial Conservation Center on April 4, 2013, and was given the deposit number KFCC11552P.
또한 상기 락토바실러스 파라카제이(Lactobacillus paracasei) MK1의 일반특성을 조사한 결과 그람 양성의 무포자형성균이고, 운동성은 없으며, catalase 활성과 gas 생성은 하지 않았다.
In addition, as a result of examining the general characteristics of the Lactobacillus paracasei MK1, it is a Gram-positive aspore-forming bacteria, has no motility, and does not produce catalase activity and gas.
실험예 5: MK1 균주의 생장 조건Experimental Example 5: Growth conditions of MK1 strain
1) 배양온도에 따른 생장율1) Growth rate according to culture temperature
MK1 균체를 두유에 접종하여 37℃에서 배양하여 균체액을 100% 두유에 2%(v/v)으로 접종하여 25, 30, 37, 및 40℃에서 24시간 배양하였으며 배양액의 생균수, 산도, pH 및 SDS-PAGE를 이용하여 배양온도에 따른 생육정도를 측정하였다. MK1 cells were inoculated into soymilk and cultured at 37°C, and the cells were inoculated with 100% soymilk at 2% (v/v) and cultured at 25, 30, 37, and 40°C for 24 hours. The degree of growth according to the culture temperature was measured using pH and SDS-PAGE.
L. paracasei MK1의 최적 배양온도를 적정 산도 및 pH로 관찰한 결과 30℃에서 24시간 발효하였을 때 0.98%로 가장 높은 산도를 보였고, pH의 경우 25℃에서 나머지 온도의 실험구보다 높은 pH 5.64로 측정되었다. 30, 37, 40℃의 24시간 발효 후 pH는 각각 4.56, 4.56, 4.54로 각 실험구마다 pH는 유사한 것으로 확인되었다(도 4a 및 도 4b). As a result of observing the optimum culture temperature of L. paracasei MK1 with appropriate acidity and pH, when fermented at 30℃ for 24 hours, the highest acidity was 0.98%, and in the case of pH, it was measured at a pH of 5.64, which is higher than the remaining temperature at 25℃. Became. After fermentation at 30, 37, and 40° C. for 24 hours, the pH was 4.56, 4.56, and 4.54, respectively, and it was confirmed that the pH was similar for each experimental group (FIGS. 4A and 4B ).
두유에 L. paracasei MK1을 접종한 후 측정한 생균수는 30℃에서 발효한 실험구가 대수증식기에 가장 먼저 진입하여 24시간 발효 시, 사멸기에 진입한 것으로 나타났다. 사멸기에 진입하였음에도 불구하고 다른 온도의 실험구보다 높은 생균수를 확인할 수 있었는데, 40℃에서 발효 시 생균수는 8.37 log CFU/mL, 37℃는 8.74 log CFU/mL, 25℃는 30℃와 유사한 8.98 log CFU/mL로 측정되었고, 30℃의 생균수는 9.03 log CFU/mL로 측정되었다(도 4c). The number of viable cells measured after inoculation of L. paracasei MK1 in soymilk was found that the experimental group fermented at 30℃ entered the logarithmic growth phase first and entered the death phase when fermented for 24 hours. Despite entering the death phase, the number of viable cells was higher than that of the experimental plots at other temperatures. When fermented at 40°C, the number of viable cells was 8.37 log CFU/mL, at 37°C 8.74 log CFU/mL, and at 25°C, 8.98 similar to 30°C. It was measured as log CFU / mL, the number of viable cells at 30 °C was measured as 9.03 log CFU / mL (Fig. 4c).
두유의 단백질 분해능은 SDS-PAGE로 확인할 수 있었는데, 0시간과 비교하면 25℃의 sample을 제외하고, 나머지 30, 37 및 40℃의 24시간 배양액의 SDS-PAGE pattern은 Fig. 13, 14에서 볼 수 있듯이 분해정도가 유사한 것으로 관찰하였다(도 5a 및 도 5b). The protein resolution of soy milk was confirmed by SDS-PAGE. Compared to 0 hours, the SDS-PAGE pattern of the 24 hour culture solution at 30, 37 and 40°C except for the sample at 25°C is shown in Fig. As can be seen in 13 and 14, it was observed that the degree of decomposition was similar (FIGS. 5A and 5B).
또한 L. paracasei MK1의 유산 생성으로 인하여 두유의 물리적 성상은 접종 12시간 이후부터 커드(curd)를 형성하였으며, 발효시간이 지날수록 커드의 경도가 높아졌다. 최종적으로 분석한 결과 두유 발효에 가장 최적의 발효온도는 30℃로 확정하였다.
In addition , due to the lactic acid formation of L. paracasei MK1, the physical properties of soy milk formed curd from 12 hours after inoculation, and the hardness of the curd increased as the fermentation time passed. As a result of the final analysis, the most optimal fermentation temperature for soy milk fermentation was determined to be 30°C.
2) 두유 희석 농도에 따른 생장율2) Growth rate according to the dilution concentration of soy milk
MK1 균체를 두유에 접종하여 37℃에서 배양하여 균체액을 25, 50, 75, 및 100% 두유에 2%(v/v)으로 접종하여 30℃에서 24시간 배양하였으며 배양액의 생균수, 산도, pH 및 SDS-PAGE를 이용하여 두유 희석에 따른 생육정도를 측정하였다. MK1 cells were inoculated into soymilk and cultured at 37°C, and the cells were inoculated at 25, 50, 75, and 100% soymilk at 2% (v/v) and cultured at 30°C for 24 hours. The degree of growth according to the dilution of soy milk was measured using pH and SDS-PAGE.
100% 두유(고형분 함량 10.8%)에서 적정 산도는 발효 18시간에서 0.90%의 높은 산도를 나타냈으며, 나머지 75% 이하의 그룹은 24시간 이후에도 적정산도가 계속적으로 증가하는 것으로 관찰되었다(도 6a). In 100% soymilk (solid content 10.8%), the titratable acidity was 0.90% at 18 hours of fermentation, and the remaining 75% or less group was observed to continuously increase the titratable acidity after 24 hours (Fig. 6a). .
적정 산도와는 달리 실험구간의 차이가 크지 않았던 pH와 생균수는 각각 24시간 발효 후 최종 pH는 약 4.6, 생균수는 8.86(100% 두유) 내지 9.12(75% 두유) log CFU/mL로 측정되어 두유의 희석이 크게 영향을 미치지 않는 것으로 보였으나(도 6b 및 도 6c), 단백질의 분해능을 SDS-PAGE로 확인한 결과 100% 및 75% 두유의 경우에는 24 시간 발효 후에도 44.3 kDa 이상의 밴드가 남아있었고, 50% 두유의 24시간 발효했을 때, 44.3 kDa 이상의 부분에서 희미한 band는 나타나지 않았다(도 7a 내지 도 7c). 25% 두유도 분해능이 좋은 것으로 나타났으나 생산성 면에서 50% 두유에 비해 불리할 것으로 판단되었다(도 7d).
Unlike the appropriate acidity, the pH and the number of viable cells, which did not differ significantly between the experimental sections, were measured at a final pH of about 4.6 after 24 hours fermentation, and the number of viable cells was 8.86 (100% soy milk) to 9.12 (75% soy milk) log CFU/mL. As a result, the dilution of soymilk did not appear to have a significant effect (FIGS. 6b and 6c), but as a result of confirming the protein resolution by SDS-PAGE, in the case of 100% and 75% soymilk, a band of 44.3 kDa or more remained after fermentation for 24 hours. And, when 50% soymilk was fermented for 24 hours, a faint band did not appear in a portion of 44.3 kDa or more (FIGS. 7a to 7c). 25% soymilk was also found to have good resolution, but was judged to be disadvantageous compared to 50% soymilk in terms of productivity (FIG. 7d).
제조예:Manufacturing example:
1) 두유 발효물의 제조1) Manufacture of fermented soy milk
멸균한 두유 또는 두유 가수분해물에 L. paracasei MK1의 colony를 접종하여 두유 발효액을 제조한 뒤, 두유 혹은 50% 두유에 2%(v/v)의 두유 발효액을 접종하여, 30℃에서 30시간 발효하였다. 발효산물은 원심분리를 통하여 그 상등액을 시료로 사용하였다.
Soymilk fermentation broth is prepared by inoculating colony of L. paracasei MK1 in sterilized soymilk or soymilk hydrolyzate, and then 2%(v/v) of soymilk fermentation broth is inoculated with soymilk or 50% soymilk, and fermented at 30℃ for 30 hours. I did. The fermentation product was centrifuged and the supernatant was used as a sample.
2) 두유 가수분해물의 제조2) Preparation of soy milk hydrolyzate
멸균한 두유 또는 두유 발효물을 효소 처리 전 50℃로 예열하였고, protamex와 flavourzyme을 단백질 kg당 효소 2 g을 첨가한 후 50℃에서 4시간 동안 격렬하게 진탕하여 반응한 후, 80℃에서 10분간 가열하여 실활시켰다.
The sterilized soy milk or fermented soy milk was preheated to 50°C before enzyme treatment, and after adding 2 g of enzyme per kg of protein to protamex and flavourzyme, reacted with vigorous shaking at 50°C for 4 hours, and then reacted at 80°C for 10 minutes. It was deactivated by heating.
3) 한외여과 분획물의 제조3) Preparation of ultrafiltration fraction
멸균한 두유, 두유 발효물 또는 두유 가수분해물을, pore size가 0.22 μm, nitrocellulose filter membrane(Sigma, USA)을 이용하여 membrane filteration으로 여과된 여액을 한외여과에 사용하였다. 한외여과기기는 Millipore사(USA)의 Lascale™ TFF system을 사용하였고, cartridge는 Millipore사의 Pellicon XL filter 중 BIOMAX, 30 K 및 5 K polyethersul- fone(50 cm2)을 사용하여 실시하였다.
The sterilized soymilk, fermented soymilk, or hydrolyzate of soybean milk, pore size 0.22 μm, filtrate filtered by membrane filteration using a nitrocellulose filter membrane (Sigma, USA) was used for ultrafiltration. The ultrafiltration device used the Lascale ™ TFF system of Millipore (USA), and the cartridge was carried out using BIOMAX, 30 K and 5 K polyethersul-fone (50 cm 2 ) among Millipore's Pellicon XL filters.
상기 1) 내지 3)의 방법을 하나 또는 2 이상 조합하여 표 5의 시료를 제조하였다. A sample of Table 5 was prepared by combining one or two or more of the methods 1) to 3) above.
50SMK
50SMKUF30
50SMKUF5
SF
SP
50SMKF
50SMKFUF30
50SMKFUF5
50SMKP
50SMKPUF30
50SMKPUF5
50SFMK
50SFMKUF30
50SFMKUF5
50SPMK
50SPMKUF30
50SPMKUF5
100S
100SMK
100SMKUF30
100SMKUF5
100SMKF
100SMKFUF30
100SMKFUF5
100SMKP
100SMKPUF30
100SMKPUF5
100SFMK
100SFMKUF30
100SFMKUF5
100SPMK
100SPMKUF30
100SPMKUF550S
50SMK
50SMKUF30
50SMKUF5
SF
SP
50SMKF
50SMKFUF30
50SMKFUF5
50SMKP
50SMKPUF30
50SMKPUF5
50SFMK
50SFMKUF30
50SFMKUF5
50SPMK
50SPMKUF30
50SPMKUF5
100S
100SMK
100SMKUF30
100SMKUF5
100SMKF
100SMKFUF30
100SMKFUF5
100SMKP
100SMKPUF30
100SMKPUF5
100SFMK
100SFMKUF30
100SFMKUF5
100SPMK
100SPMKUF30
50% Soymilk → Fermented with L. paracasei MK1
50% Soymilk → Fermented with L. paracasei MK1 → UF 30 kDa
50% Soymilk → Fermented with L. paracasei MK1 → UF 30 kDa → UF 5 kDa
100% Soymilk → Flavourzyme
100% Soymilk → Protamex
50% Soymilk → Fermented with L. paracasei MK1 → Flavourzyme
50% Soymilk → Fermented with L. paracasei MK1 → Flavourzyme → UF 30 kDa
50% Soymilk → Fermented with L. paracasei MK1 → Flavourzyme → UF 30 kDa → UF 5 kDa
50% Soymilk → Fermented with L. paracasei MK1 → Protamex
50% Soymilk → Fermented with L. paracasei MK1 → Protamex → UF 30 kDa
50% Soymilk → Fermented with L. paracasei MK1 → Protamex → UF 30 kDa → UF 5 kDa
50% Soymilk → Flavorzyme → Fermented with L. paracasei MK1
50% Soymilk → Flavorzyme → Fermented with L. paracasei MK1 → UF 30 kDa
50% Soymilk → Flavorzyme → Fermented with L. paracasei MK1 → UF 30 kDa → UF 5 kDa
50% Soymilk → Protamex → Fermented with L. paracasei MK1
50% Soymilk → Protamex → Fermented with L. paracasei MK1 → UF 30 kDa
50% Soymilk → Protamex → Fermented with L. paracasei MK1 → UF 30 kDa → UF 5 kDa
100% Soymilk
100% Soymilk → Fermented with L. paracasei MK1
100% Soymilk → Fermented with L. paracasei MK1 → UF 30 kDa
100% Soymilk → Fermented with L. paracasei MK1 → UF 30 kDa → UF 5 kDa
100% Soymilk → Fermented with L. paracasei MK1 → Flavourzyme
100% Soymilk → Fermented with L. paracasei MK1 → Flavourzyme → UF 30 kDa
100% Soymilk → Fermented with L. paracasei MK1 → Flavourzyme → UF 30 kDa → UF 5 kDa
100% Soymilk → Fermented with L. paracasei MK1 → Protamex
100% Soymilk → Fermented with L. paracasei MK1 → Protamex → UF 30 kDa
100% Soymilk → Fermented with L. paracasei MK1 → Protamex → UF 30 kDa → UF 5 kDa
100% Soymilk → Flavorzyme → Fermented with L. paracasei MK1
100% Soymilk → Flavorzyme → Fermented with L. paracasei MK1 → UF 30 kDa
100% Soymilk → Flavorzyme → Fermented with L. paracasei MK1 → UF 30 kDa → UF 5 kDa
100% Soymilk → Protamex → Fermented with L. paracasei MK1
100% Soymilk → Protamex → Fermented with L. paracasei MK1 → UF 30 kDa
100% Soymilk → Protamex → Fermented with L. paracasei MK1 → UF 30 kDa → UF 5 kDa50% Soymilk
50% Soymilk → Fermented with L. paracasei MK1
50% Soymilk → Fermented with L. paracasei
50% Soymilk → Fermented with L. paracasei
100% Soymilk → Flavourzyme
100% Soymilk → Protamex
50% Soymilk → Fermented with L. paracasei MK1 → Flavourzyme
50% Soymilk → Fermented with L. paracasei MK1 →
50% Soymilk → Fermented with L. paracasei MK1 →
50% Soymilk → Fermented with L. paracasei MK1 → Protamex
50% Soymilk → Fermented with L. paracasei MK1 →
50% Soymilk → Fermented with L. paracasei MK1 →
50% Soymilk → Flavorzyme → Fermented with L. paracasei MK1
50% Soymilk → Flavorzyme → Fermented with L. paracasei
50% Soymilk → Flavorzyme → Fermented with L. paracasei
50% Soymilk → Protamex → Fermented with L. paracasei MK1
50% Soymilk → Protamex → Fermented with L. paracasei
50% Soymilk → Protamex → Fermented with L. paracasei
100% Soymilk
100% Soymilk → Fermented with L. paracasei MK1
100% Soymilk → Fermented with L. paracasei
100% Soymilk → Fermented with L. paracasei
100% Soymilk → Fermented with L. paracasei MK1 → Flavourzyme
100% Soymilk → Fermented with L. paracasei MK1 →
100% Soymilk → Fermented with L. paracasei MK1 →
100% Soymilk → Fermented with L. paracasei MK1 → Protamex
100% Soymilk → Fermented with L. paracasei MK1 →
100% Soymilk → Fermented with L. paracasei MK1 →
100% Soymilk → Flavorzyme → Fermented with L. paracasei MK1
100% Soymilk → Flavorzyme → Fermented with L. paracasei
100% Soymilk → Flavorzyme → Fermented with L. paracasei
100% Soymilk → Protamex → Fermented with L. paracasei MK1
100% Soymilk → Protamex → Fermented with L. paracasei
100% Soymilk → Protamex → Fermented with L. paracasei
실험예 6: 고형분 함량Experimental Example 6: Solid content
상기 제조예의 시료들의 항산화, 피부세포에 대한 세포성장 및 독성, procollagen 생성량, TNF-α의 생성량을 측정하기에 앞서, 각각 시료들의 고형분 함량을 측정하여 표 6에 나타내었다. Before measuring the antioxidant, cell growth and toxicity to skin cells, procollagen production amount, and TNF-α production amount of the samples of Preparation Example, the solid content of each sample was measured and shown in Table 6.
50SMK
50SMKUF30
50SMKUF5
SF
SP
50SMKF
50SMKFUF30
50SMKFUF5
50SMKP
50SMKPUF30
50S
50SMK
50SMKUF30
50SMKUF5
SF
SP
50SMKF
50SMKFUF30
50SMKFUF5
50SMKP
50SMKPUF30
1.42
1.30
1.13
ND1)
ND
1.65
1.38
1.30
1.45
1.34
3.51
1.42
1.30
1.13
ND 1)
ND
1.65
1.38
1.30
1.45
1.34
50SFMK
50SFMKUF30
50SFMKUF5
50SPMK
50SPMKUF30
50SPMKUF5
100S
100SMK
100SMKUF30
100SMKUF5
50SMKPUF5
50SFMK
50SFMKUF30
50SFMKUF5
50SPMK
50SPMKUF30
50SPMKUF5
100S
100SMK
100SMKUF30
100SMKUF5
1.97
1.65
1.37
2.70
2.34
1.85
ND
2.58
2.05
1.70
1.18
1.97
1.65
1.37
2.70
2.34
1.85
ND
2.58
2.05
1.70
100SMKFUF30
100SMKFUF5
100SMKP
100SMKPUF30
100SMKPUF5
100SFMK
100SFMKUF30
100SFMKUF5
100SPMK
100SPMKUF30
100SPMKUF5100SMKF
100SMKFUF30
100SMKFUF5
100SMKP
100SMKPUF30
100SMKPUF5
100SFMK
100SFMKUF30
100SFMKUF5
100SPMK
100SPMKUF30
100SPMKUF5
2.96
2.45
3.10
1.66
1.36
3.31
2.88
2.58
4.10
3.22
2.453.30
2.96
2.45
3.10
1.66
1.36
3.31
2.88
2.58
4.10
3.22
2.45
1)ND는 Not detemided의 약어임 1) ND stands for Not detemided
상기 표 6에 나타낸 바와 같이, 100SF, 100SP, 및 100S(100% 두유)는 filtration이 불가능하여 제외하였다. As shown in Table 6, 100SF, 100SP, and 100S (100% soymilk) were excluded because filtration was impossible.
고형분 함량이 가장 높은 100SPMK는 100% 두유를 protamex 처리 후 L. paracasei MK1으로 발효시킨 시료로서 4.10%의 높은 고형분 함량을 나타냈고, 1.13%의 가장 낮은 고형분 함량을 나타낸 50SMKUF5은 50% 두유를 L. paracasei MK1로 발효하여 한외여과를 이용하여 5 kDa 미만의 분획을 얻은 것으로 큰 분자량의 단백질은 제거된 상태였다. 100SPMK, which has the highest solids content, is a sample fermented with L. paracasei MK1 after protamex treatment of 100% soymilk. It showed a high solids content of 4.10%, and 50SMKUF5, which showed the lowest solids content of 1.13%, contained 50% soymilk in L. By fermentation with paracasei MK1, a fraction of less than 5 kDa was obtained by ultrafiltration, and proteins of large molecular weight were removed.
전반적인 경향은 100% 두유를 이용하여 제조한 시료들은 50% 두유보다 고형분 함량에 있어 1.5-1.7배의 차이를 나타냈고, 발효와 한외여과를 진행할수록 고형분의 함량은 감소하는 경향을 보였다. 이는 초기의 희석배수가 고형분 함량에도 영향을 미치며, 한외여과를 진행함으로써 고형분 함량에 근소한 영향을 주는 것이라고 사료된다.
The overall trend was that the samples prepared using 100% soymilk showed a difference of 1.5-1.7 times in solid content compared to 50% soymilk, and the solid content tended to decrease as fermentation and ultrafiltration proceeded. This is thought that the initial dilution factor also affects the solid content, and it is thought that the ultrafiltration has a slight effect on the solid content.
실험예 7: 세포독성Experimental Example 7: Cytotoxicity
1) 세포 배양1) cell culture
Collagen 생성에 관여하는 진피 세포주인 Normal Human dermal fibroblast(ATCC, VA)와 주름의 주요한 원인 중 하나인 염증 반응을 완화시키는 효과가 있는지 평가하기 위하여 표피세포주인 Immotalized human keratinocyte(HaCaT)을 1% antibiotic-antimycotic(AA, Welgene, Korea)와 10% fetal bovine serum(FBS, Welgene, Korea)을 포함한 Dulbecco's modified essential medium(DMEM, Welgene, Korea)을 이용하여 37℃에서 5% CO2 조건으로 배양하였다.
In order to evaluate whether the dermal cell line involved in collagen production, Normal Human dermal fibroblast (ATCC, VA) and the epidermal cell line Immotalized human keratinocyte (HaCaT), were 1% antibiotic- Dulbecco's modified essential medium (DMEM, Welgene, Korea) containing antimycotic (AA, Welgene, Korea) and 10% fetal bovine serum (FBS, Welgene, Korea) was incubated at 37°C under 5% CO 2 conditions.
2) MTT 분석2) MTT analysis
MTT assay는 세포의 미토콘드리아에 있는 mitochondrial succinate dehydrogenase가 MTT(yellow)를 환원시켜 생성된 formazan(purple)의 흡광도를 측정하여 대사적으로 왕성한 세포의 농도를 반영하는 방법으로, 본 연구에서는 시료를 고형분 함량 0.02%에서 1/2씩 희석하여 다양한 농도로 세포에 처리하고 24시간 동안 배양한 후 Fibroblast와 HaCaT 세포를 사용하였고, 대조군으로는 시료를 처리하지 않은 세포를 사용하였다.
MTT assay is a method that reflects the concentration of metabolically active cells by measuring the absorbance of formazan (purple) produced by reducing MTT (yellow) by mitochondrial succinate dehydrogenase in the mitochondria of cells. After diluting by 1/2 at 0.02%, treating the cells at various concentrations and incubating for 24 hours, Fibroblast and HaCaT cells were used, and cells without sample treatment were used as a control.
3) 분석 결과3) Analysis result
Fibroblast 세포의 생존율은 시료의 농도에 의존적이지 않았고, fibroblast의 경우 농도가 높아지며 생존율이 증가함을 보였으며, 특히 100% 두유를 protamex 효소 처리 후, L. paracasei MK1으로 발효하고 한외여과를 통하여 5 kDa 미만으로 여과한 여액인 100SPMKUF5는 2.50×10-2의 농도에서 다른 시료들 중에서 가장 높은 129.67%의 생장률을 나타냈다. 또한 50SMKF는 3.13×10-3의 농도부터 122.85% 이상의 cell 생존율을 보였다. 100% 두유로 처리한 시료들과 50% 두유로 처리한 시료들은 서로의 차이는 발견할 수 없었지만, 1.25×10-2 이상의 농도에서는 거의 모든 시료가, 시료를 처리하지 않은 세포들보다 높은 생존율을 보였다(데이터 미첨부).
The viability of fibroblast cells was not dependent on the concentration of the sample. In the case of fibroblast, the concentration increased and the survival rate increased. In particular, 100% soymilk was fermented with L. paracasei MK1 after protamex enzyme treatment and 5 kDa through ultrafiltration through ultrafiltration. 100SPMKUF5, the filtrate filtered below, showed the highest growth rate of 129.67% among other samples at a concentration of 2.50×10 -2. In addition, 50SMKF showed a cell survival rate of 122.85% or more from a concentration of 3.13×10 -3. The samples treated with 100% soymilk and samples treated with 50% soymilk could not find any difference, but at concentrations higher than 1.25×10 -2 , almost all samples had a higher viability than cells that were not treated with the sample. Showed (data not attached).
항염증 반응을 확인할 수 있는 HaCaT 세포의 경우 최종 농도인 0.1%에서 생존율이 높았던 시료와 생존율은 50SFMKUF5 103.71%, 50SMKP 102.02%, 50SFMKUF30 101.83%, 50SPMK 101.45%, 100SMK 101.41%, 50SFMK 100.7%, 100SPMK는 100.23%로 나타났고, 이들 시료를 제외하고는 100SMKFUF5로 59.63%로 가장 낮은 생존율을 나나내었고, 대부분 세포독성을 나타낸 것으로 나타났다(도 8a 내지 도 8j). In the case of HaCaT cells with an anti-inflammatory response, the sample and the survival rate of which the survival rate was high at the final concentration of 0.1% were 50SFMKUF5 103.71%, 50SMKP 102.02%, 50SFMKUF30 101.83%, 50SPMK 101.45%, 100SMK 101.41%, 50SFMK 100.7%, and 100SPMK. 100.23%, except for these samples, showed the lowest survival rate of 59.63% with 100SMKFUF5, and most of them showed cytotoxicity (FIGS. 8A to 8J).
또한 전반적으로 HaCaT 세포에 있어서 50% 두유로 진행한 시료보다 100% 두유로 진행한 시료가 cell 생존율이 낮은 것으로 나타났고, 이를 통해서 50%의 두유로 진행한 시료를 2차 시료로 선정하였다.
In addition, in the overall HaCaT cells, it was found that the cell viability of the sample proceeded with 100% soymilk was lower than that of the sample proceeded with 50% soymilk.
실험예 8: I형 프로콜라겐 생성량 분석Experimental Example 8: Analysis of I-type procollagen production
1) 세포배양1) Cell culture
Collagen 생성에 관여하는 진피 세포주인 Normal Human dermal fibroblast(ATCC, VA)를 1% antibiotic-antimycotic(AA, Welgene, Korea)와 10% fetal bovine serum(FBS, Welgene, Korea)을 포함한 Dulbecco's modified essential medium(DMEM, Welgene, Korea)을 이용하여 37℃에서 5% CO2 조건으로 배양하였다.
Dulbecco's modified essential medium containing 1% antibiotic-antimycotic (AA, Welgene, Korea) and 10% fetal bovine serum (FBS, Welgene, Korea), which is a dermal cell line involved in collagen production (ATCC, VA). DMEM, Welgene, Korea) was incubated at 37°C under 5% CO 2 conditions.
2) I형 프로콜라겐 생성량 분석2) Analysis of I-type procollagen production
Fibroblast를 6 well plate에 2×105 cell을 접종하여 24시간 동안 배양한 후, 배지를 제거한 뒤 무혈청 배지를 처리하여 24시간 동안 starvation하였다. Starvation 후, 배지를 제거한 뒤 PBS(phosphate buffered saline, Amresco, USA)로 세척하였다. PBS 존재 하에 312 nm에서 25 mJ로 조사하고, 시료를 FBS가 함유되어 있지 않은 DMEM 배지를 넣고 시료를 농도 별로 처리하여 48시간 동안 추가 배양하였다. 배양 후, 수거한 배지를 procollagen type-I C-Peptide(PIP) EIA kit(Takara Bio, Inc., MK101, Japan)를 이용하여 생성되는 콜라겐을 측정하였다. 양성 대조군(positive control)으로 50 μM ascorbic acid로 사용하였고, 음성 대조군(negative control)으로 UV를 처리하지 않은 시험구로 이용하며, 배지만 처리한 시료를 대조군(control)으로 사용하였다.
Fibroblast was inoculated with 2×10 5 cells in a 6 well plate and incubated for 24 hours, and then the medium was removed and then starvation was performed for 24 hours by treatment with a serum-free medium. After starvation, the medium was removed and washed with PBS (phosphate buffered saline, Amresco, USA). In the presence of PBS, irradiation was performed at 312 nm at 25 mJ, the sample was added to DMEM medium containing no FBS, and the sample was treated for each concentration, followed by further incubation for 48 hours. After cultivation, the collected medium was measured for collagen produced using a procollagen type-I C-Peptide (PIP) EIA kit (Takara Bio, Inc., MK101, Japan). As a positive control, 50 μM ascorbic acid was used, as a negative control, a test group that was not UV-treated, and a sample treated with only the medium was used as a control.
3) 분석 결과3) Analysis result
실험예 7의 HaCat 세포에 세포독성을 나타내지 않은 50% 두유를 처리한 시료 50SFMKUF5, 50SMKP, 50SFMKUF30, 50SPMK 및 50SFMK를 양성 대조군인 ascorbic acid와 비교하였고, 고형분 함량 대비 0.1, 0.01, 0.001%의 농도로 시료를 처리하였으며, MK1으로 발효시키지 않은 50S를 대조군으로 함께 비교하여 도 9a 내지 도 9e에 나타내었다. Samples treated with 50% soymilk, which did not show cytotoxicity to HaCat cells of Experimental Example 7, 50SFMKUF5, 50SMKP, 50SFMKUF30, 50SPMK and 50SFMK were compared with ascorbic acid as a positive control, and at a concentration of 0.1, 0.01, 0.001% relative to the solid content. Samples were treated, and 50S not fermented with MK1 were compared together as a control, and are shown in FIGS. 9A to 9E.
50 μM ascorbic acid를 처리하였을 때의 양성 대조군은 50 μM에서 197.76%로 측정되었으며, 대조군보다 높은 시료는 고형분 함량이 0.1%일 때, 246.94%로 측정된 50SPMK이다. 50SPMK를 제외하고 대조군과 유사한 범위내의 시료는 50SFMKUF5로 확인되었는데, 50SFMKUF5는 50% 두유를 flavourzyme으로 처리한 후, L. paracasei MK1으로 발효한 뒤, 한외여과를 통하여 5 kDa 미만의 분획의 시료이다. 50SFMKUF5는 대조군보다 약간 적은 164.23%의 procollagen 양을 나타내었지만, 모든 농도에 있어 160% 이상으로 적지 않은 procollagen을 확인할 수 있었다.
The positive control when treated with 50 μM ascorbic acid was measured as 197.76% at 50 μM, and the sample higher than the control was 50 SPMK measured as 246.94% when the solid content was 0.1%. Except for 50SPMK, a sample within a range similar to that of the control was identified as 50SFMKUF5, and 50SFMKUF5 was a sample of a fraction of less than 5 kDa through ultrafiltration after fermenting with L. paracasei MK1 after treating 50% soy milk with flavourzyme. 50SFMKUF5 showed a slightly lower amount of procollagen of 164.23% than that of the control group, but not less than 160% of procollagen could be confirmed at all concentrations.
실험예Experimental example 9: 9: TNFTNF -α의 생성량 분석-α production analysis
1) TNF-α의 생성량 분석1) Analysis of the amount of TNF-α produced
HaCaT 세포를 12 well plate에 1×105 cell을 접종하여 24시간 동안 배양한 후, TNF-α를 유도시키기 위하여 UV 조사와 함께 시료를 농도별로 처리하여 24시간 추가 배양하였다. UV 조사하지 않은 그룹과 UV 조사 후 dexamethasone을 1 μM/mL 처리한 그룹을 대조군으로 사용하여 시료의 결과와 비교하였다. 312 nm에서 12.5 mJ로 조사하고, 시료를 24시간 동안 배양 후 배지로 분비되어지는 TNF-α는 kit(Invitrogen, #KHC3012, USA)를 사용하여 450 nm에서 흡광도를 측정하였다.
HaCaT cells were inoculated with 1×10 5 cells in a 12 well plate and cultured for 24 hours, and then, in order to induce TNF-α, samples were treated by concentration with UV irradiation and cultured for an additional 24 hours. The group without UV irradiation and the group treated with 1 μM/mL of dexamethasone after UV irradiation were used as controls and compared with the results of the sample. After irradiation at 312 nm with 12.5 mJ, the sample was cultured for 24 hours, and then TNF-α secreted into the medium was measured for absorbance at 450 nm using a kit (Invitrogen, #KHC3012, USA).
2) 분석 결과2) Analysis result
대조군은 UV를 조사한 HaCaT을 100%로 하고, 양성 대조군은 강력한 항염증제로 사용되는 덱사메타손을 사용하였다. 실험예 7의 HaCat 세포에 세포독성을 나타내지 않은 50% 두유를 처리한 시료 50SFMKUF5, 50SMKP, 50SFMKUF30, 50SPMK 및 50SFMK를 양성 대조군인 덱사메타손과 비교하여 도 10a 내지 도 10e에 나타내었다. The control group was 100% UV-irradiated HaCaT, and the positive control group used dexamethasone, which is a strong anti-inflammatory agent. Samples 50SFMKUF5, 50SMKP, 50SFMKUF30, 50SPMK and 50SFMK samples treated with 50% soymilk that did not show cytotoxicity to HaCat cells of Experimental Example 7 are shown in FIGS. 10A to 10E in comparison with the positive control dexamethasone.
Dexamethasone을 처리한 양성 대조군의 TNF-α의 생성량은 65.58%로 모든 농도(0.1, 0.02, 0.004, 0.0008%)에서 양성 대조군보다 낮은 값을 보인 시료는 50SFMKUF30 및 50SFMKUF5로서 이 중 50SFMKUF5도 0.02%의 농도에서 23.44%의 TNF-α가 검출되어 50SFMKUF5는 TNF-α 생성을 억제하는 것으로 확인되었다.
The amount of TNF-α produced in the positive control treated with dexamethasone was 65.58%, and the samples showing lower values than the positive control at all concentrations (0.1, 0.02, 0.004, 0.0008%) were 50SFMKUF30 and 50SFMKUF5, of which 50SFMKUF5 also had a concentration of 0.02%. In 23.44% of TNF-α was detected, 50SFMKUF5 was confirmed to inhibit the production of TNF-α.
실험예Experimental example 10: 50 10: 50 SFMKUF5SFMKUF5 및 5 And 5 kDakDa 이하 분획의 성분 분석 Component analysis of the following fractions
1) 유리아미노산 분석1) Free amino acid analysis
상기 선정한 50% 두유 희석액을 한외여과를 통해 5 kDa 미만의 분획물인 50SMKUF5, 50SMKFUF5, 50SMKPUF5, 50SFMKUF5, 50SPMKUF5의 5가지 시료에 대한 유리 아미노산 분석을 실시하여 표 7에 나타내었다. The selected 50% soymilk dilution was subjected to ultrafiltration to analyze free amino acids for five samples of 50SMKUF5, 50SMKFUF5, 50SMKPUF5, 50SFMKUF5, and 50SPMKUF5 fractions of less than 5 kDa through ultrafiltration, and are shown in Table 7.
1)TA : Total free amino acid 1) TA: Total free amino acid
2)EA : Essential amino acid (Thr+Val+Met+Ile+Leu+Phe+Lys+Trp+His)
2) EA: Essential amino acid (Thr+Val+Met+Ile+Leu+Phe+Lys+Trp+His)
효소처리를 하지 않은 50SMKUF5이 가장 낮은 40.2 mg/100 g의 값을 나타냈고, 발효 후 효소처리한 50SMKFUF5, 50SMKPUF5보다 효소처리 후 발효한 50SFMKUF5, 50SPMKUF5의 유리아미노산 함량이 더 높았다. 50SFMKUF5의 유리 아미노산 함량은 67.3 mg/100 g으로 가장 높았고, 50SMKFUF5는 46.8 mg/100 g으로 측정되었다. 이는 효소처리를 먼저 함으로서 두유의 단백질을 L. paracasei MK1이 더욱 효과적으로 절단할 수 있었기 때문에 효소 처리를 먼저 진행한 시료들이 그렇지 않은 시료들보다 유리 아미노산 함량이 높았던 것으로 사료된다. 50SMKUF5 without enzyme treatment showed the lowest value of 40.2 mg/100 g, and the free amino acid content of 50SFMKUF5 and 50SPMKUF5 fermented after enzyme treatment was higher than 50SMKFUF5 and 50SMKPUF5 enzyme treatment after fermentation. The free amino acid content of 50SFMKUF5 was the highest at 67.3 mg/100 g, and 50SMKFUF5 was measured at 46.8 mg/100 g. This is because L. paracasei MK1 could more effectively cleave the protein of soy milk by enzymatic treatment first, so it is thought that the samples subjected to the enzyme treatment had higher free amino acid content than the samples without the enzyme treatment.
유리 아미노산 중 필수 아미노산의 함량은 50SFMKUF5가 36.2 mg/100 g으로 가장 높은 함량을 나타냈고, 전체 아미노산의 53.9%를 차지하였다. 반면 50SMKUF5는 6.9 mg/ 100 g으로 가장 높은 50SFMKUF5의 약 6배 차이가 있는 것으로 나타났다. 또한 효소 처리를 하지 않은 50SMKUF5는 flavourzyme이나 protamex를 처리한 시료의 필수 아미노산의 함량이 낮은 것으로 확인되었다. Flavourzyme을 처리한 시료인 50SMKFUF5, 50SFMKUF5의 필수 아미노산 함량은 각각 13.1, 36.2 mg/100 g이었고, protamex를 처리한 시료인 50SMKPUF5, 50SPMKUF5의 필수 아미노산 함량은 8.4, 21.2 mg/100 g으로 flavourzyme을 처리한 시료가 더 높은 필수 아미노산 함량을 나타내었다. 이는 효소가 기질에 작용하는 범위가 차이가 있는 것으로 판단되며, 두유 발효에 있어서 L. paracasei MK1이 이용하는데 효소처리를 하지 않은 것보다 효소처리를 하는 것이 두유 단백질의 분해가 더욱 잘 일어난 것으로 판단되며, protamex보다 flavouzyme이 더 효과적임을 시사하는 바이다.
As for the content of essential amino acids among free amino acids, 50SFMKUF5 showed the highest content of 36.2 mg/100 g, accounting for 53.9% of the total amino acids. On the other hand, 50SMKUF5 was found to have a difference of about 6 times that of 50SFMKUF5, the highest at 6.9 mg/100 g. In addition, 50SMKUF5 without enzyme treatment was found to have a low content of essential amino acids in samples treated with flavourzyme or protamex. Flavourzyme-treated samples 50SMKFUF5 and 50SFMKUF5 had an essential amino acid content of 13.1 and 36.2 mg/100 g, respectively, and protamex-treated samples 50SMKPUF5 and 50SPMKUF5 had an essential amino acid content of 8.4 and 21.2 mg/100 g. Samples showed higher essential amino acid content. It is judged that there is a difference in the range in which the enzyme acts on the substrate, and L. paracasei MK1 is used in soymilk fermentation. , This suggests that flavouzyme is more effective than protamex.
2) 총질소 및 TCA 용해 질소 함량 분석2) Total nitrogen and TCA dissolved nitrogen content analysis
시료의 총 질소함량과 TCA 용해 질소함량을 통하여 발효 및 효소처리에 의한 질소 함량 변화를 측정하였다. 총 질소 함량은 시료에 존재하는 모든 peptide나 단백질의 양을 추정할 수 있으며, TCA 용해 질소의 함량은 protease에 의하여 단백질이 가수분해 되어 나타난 질소 화합물의 함량을 가늠할 수 있는 의미가 있다. Changes in nitrogen content by fermentation and enzyme treatment were measured through the total nitrogen content of the sample and the dissolved nitrogen content of TCA. The total nitrogen content can estimate the amount of all peptides or proteins present in the sample, and the content of nitrogen dissolved in TCA is meaningful to estimate the content of nitrogen compounds generated by hydrolysis of proteins by protease.
(mg N/100 mL)(mg N/100 mL)
(mg N/100 mL)(mg N/100 mL)
50SMKUF5
50SMKFUF5
50SMKPUF5
50SFMKUF5
50SPMKUF550S
50SMKUF5
50SMKFUF5
50SMKPUF5
50SFMKUF5
50SPMKUF5
0.34±0.07
0.60±0.14
0.40±0.09
1.22±0.23
1.60±0.222.82±0.17
0.34±0.07
0.60±0.14
0.40±0.09
1.22±0.23
1.60±0.22
0.12±0.05
0.36±0.03
0.23±0.01
0.45±0.02
0.82±0.060.12±0.03
0.12±0.05
0.36±0.03
0.23±0.01
0.45±0.02
0.82±0.06
36.17
59.59
58.02
36.93
51.164.39
36.17
59.59
58.02
36.93
51.16
표 8에 나타난 바와 같이 어떠한 처리도 하지 않은 50S는 총 질소함량이 2.82 mg N/100 mL로 나타났고, 50SPMKUF5가 1.60 mg N/100 mL로 측정되었다. 총 질소함량에 있어 가장 낮은 값을 나타낸 50SMKUF5는 0.34 mg N/100 mL로 확인하였다. 이는 최대 총 질소함량이 최대 50% 미만까지 감소함을 보였다. 또한 최종선발균주인 L. paracasei MK1으로 발효한 50SMKUF5와 발효 후 효소 처리한 50SMKFUF5, 50SMKPUF5는 총 질소함량의 큰 차이가 없었고, flavourzyme과 protamex로 처리한 후 발효를 거쳐 한외여과를 한 시료인 50SFMKUF5, 50SPMKUF5는 총 질소함량이 50SMKUF5, 50SMKFUF5, 50SMKPUF5의 2배 이상으로 측정되었다. As shown in Table 8, 50S without any treatment showed a total nitrogen content of 2.82 mg N/100 mL, and 50SPMKUF5 was measured as 1.60 mg N/100 mL. 50SMKUF5, which showed the lowest value in terms of total nitrogen content, was found to be 0.34 mg N/100 mL. This showed that the maximum total nitrogen content was reduced by up to less than 50%. In addition, 50SMKUF5 fermented with L. paracasei MK1, the final selection strain, and 50SMKFUF5 and 50SMKPUF5 fermented after fermentation, had no significant difference in total nitrogen content. The total nitrogen content of 50SPMKUF5 was measured to be more than twice that of 50SMKUF5, 50SMKFUF5, and 50SMKPUF5.
TCA 용해 질소함량을 통해 효소처리에 의한 비단백태 질소의 함량을 볼 수 있었는데, 이 결과 역시 50SFMKUF5와 50SPMKUF5가 각각 0.45, 0.82 mg N/100 mL로 총 질소함량과 유사한 경향임을 관찰하였다. 효소처리를 먼저 한 것이 비단백태 질소함량이 높은 것으로 측정되었다. 두유에 먼저 효소제로 인하여 가수분해가 일어났기 때문에 TCA 용해 질소함량이 높은 것으로 사료되고, 발효 후 효소처리한 것은 이미 최종선발균주로 인하여 가수분해가 일어났기 때문에 효소제의 영향이 적은 것으로 판단되는데, TCA 용해 질소의 함량이 시료 50S와 50SMKUF5가 큰 차이가 없는 것으로 알 수 있었다.
Through the nitrogen content of TCA dissolved, the content of non-protein nitrogen by enzyme treatment was observed, and as a result, it was observed that 50SFMKUF5 and 50SPMKUF5 were 0.45 and 0.82 mg N/100 mL, respectively, similar to the total nitrogen content. The first enzyme treatment was determined to have a high content of non-proteinaceous nitrogen. Since the soymilk was first hydrolyzed due to an enzyme agent, it is believed that the nitrogen content of TCA dissolved is high, and the enzyme treatment after fermentation is considered to have little effect from the enzyme agent because hydrolysis has already occurred due to the final selected strain. It was found that the content of
3) 일반성분 분석3) General component analysis
상기 실험예 7 및 8을 통해 선정한 50SFMKUF5 분획물과 100% 두유의 일반성분의 차이점을 분석하기 위하여 100% 두유의 일반성분은 표 9에 나타내었다. In order to analyze the difference between the 50SFMKUF5 fraction selected through Experimental Examples 7 and 8 and the general ingredients of 100% soymilk, the general ingredients of 100% soymilk are shown in Table 9.
Carbohydrate (g/100 g)
Crude protein (g/100 g)
Crude lipid (g/100 g)
Solid (%)Saccharide (g/100 g)
Carbohydrate (g/100 g)
Crude protein (g/100 g)
Crude lipid (g/100 g)
Solid (%)
3.40
4.30
2.40
10.80.71
3.40
4.30
2.40
10.8
ND
0.30
0.00
1.37ND 1)
ND
0.30
0.00
1.37
1)ND는 Not detemided의 약어임 1) ND stands for Not detemided
100 g당 당류는 0.71 g, 탄수화물 3.40 g, 조단백질 4.30 g, 조지방 2.40 g의 함량을 나타내었으며, 고형분 함량은 10.8%로 측정되었다. 50SFMKUF5의 조단백질은 0.30 g으로 나타났으며, 조지방의 함량은 0.00 g, 고형분은 1.37%로 확인되었다. 모든 일반성분은 100% 두유보다 낮은 값을 나타냈고, 이는 발효와 ultrafilt- ration으로 인한 감소로 판단할 수 있었다. Sugars per 100 g were 0.71 g, carbohydrates 3.40 g, crude protein 4.30 g, crude fat 2.40 g, and the solid content was measured to be 10.8%. The crude protein of 50SFMKUF5 was found to be 0.30 g, the content of crude fat was 0.00 g, and the solid content was 1.37%. All general ingredients showed lower values than 100% soymilk, which could be judged by the decrease due to fermentation and ultrafiltration.
4) 펩타이드 분석4) Peptide analysis
상기 실험예 7 및 8을 통해 선정한 50SFMKUF5 분획물을 LC/MS-MS를 사용하여 peptide mapping을 진행하였다. LC chromatogram은 도 11a에 나타내었고, retention time이 19.03-46.54분에 대부분의 peak가 존재하였다. Retention time 19.25-48.28분의 구간을 선정한 MS chromatogram을 도 11 b에 나타내었다. 분자량 953.48-4770.20 kDa의 peptide peak 사이에 major peak는 m/z값이 726.87이고, 이 peak의 분자량 1453.74 kDa의 peptide로 확인되었다. 이 peptide는 콩 유래의 data base상에서 검색한 결과(NCBI, USA) Glycinin G2로 나타났고, 그 아미노산서열은 APEFLKEAFGVN으로 확인하였다.
The 50SFMKUF5 fraction selected through Experimental Examples 7 and 8 was subjected to peptide mapping using LC/MS-MS. The LC chromatogram is shown in FIG. 11A, and most of the peaks were present at the retention time of 19.03-46.54 minutes. The MS chromatogram selecting the interval between 19.25-48.28 minutes of retention time is shown in FIG. 11B. The major peak between the peptide peaks having a molecular weight of 953.48-4770.20 kDa has an m/z value of 726.87, and this peak was identified as a peptide with a molecular weight of 1453.74 kDa. This peptide was found as Glycinin G2 as a result of searching on the data base derived from soybean (NCBI, USA), and its amino acid sequence was confirmed as APEFLKEAFGVN.
이하, 하기 조성에 따라서, 각각 비누형, 로션형, 크림형, 팩형, 미용액형의 제제들을 제조하였다. Hereinafter, according to the following composition, each of the soap-type, lotion-type, cream-type, pack-type, and cosmetic liquid-type formulations were prepared.
제조예 1. 비누형Manufacturing Example 1. Soap type
50SFMKUF5 분획물
5
유지 75maintain 75
수산화나트륨
5
향료
10
정제수 잔량Purified water Balance
(단위: 중량%)
(Unit: wt%)
제조예 2. 로션형Manufacturing Example 2. Lotion type
50SFMKUF5 분획물 3.0050SFMKUF5 fraction 3.00
L-아스코르빈산-2-인산마그네슘염 1.00L-ascorbic acid-2-phosphate magnesium salt 1.00
수용성 콜라겐 (1% 수용액) 1.00Water-soluble collagen (1% aqueous solution) 1.00
시트르산나트륨 0.10Sodium citrate 0.10
시트르산 0.05Citric acid 0.05
감초 엑기스 0.20Licorice extract 0.20
1,3-부틸렌글리콜 3.001,3-butylene glycol 3.00
정제수 잔량Purified water Balance
(단위: 중량%)
(Unit: wt%)
제조예 3. 크림형Manufacturing Example 3. Cream type
50SFMKUF5 분획물 1.0050SFMKUF5 fraction 1.00
폴리에틸렌글리콜모노스테아레이트 2.00 Polyethylene glycol monostearate 2.00
자기유화형 모노스테아르산글리세린 5.00Self-emulsifying glycerin monostearate 5.00
세틸알코올 4.00Cetyl alcohol 4.00
스쿠알렌 6.00Squalene 6.00
트리2-에틸헥산글리세릴 6.00Tri2-ethylhexane glyceryl 6.00
스핑고당지질 1.00Sphingoglycolipid 1.00
1.3-부틸렌글리콜 7.001.3-butylene glycol 7.00
정제수 잔량Purified water Balance
(단위: 중량%)
(Unit: wt%)
제조예 4. 팩형Manufacturing Example 4. Packed
50SFMKUF5 분획물 5.0050SFMKUF5 fraction 5.00
폴리비닐알코올 13.00Polyvinyl alcohol 13.00
L-아스코르빈산-2-인산마그네슘염 1.00L-ascorbic acid-2-phosphate magnesium salt 1.00
라우로일히드록시프롤린 1.00Lauroylhydroxyproline 1.00
수용성 콜라겐 (1% 수용액) 2.00Water-soluble collagen (1% aqueous solution) 2.00
1,3-부틸렌글리콜 3.001,3-butylene glycol 3.00
에탄올 5.00ethanol 5.00
정제수 잔량Purified water Balance
(단위: 중량%)
(Unit: wt%)
제조예 5. 미용액형Manufacturing Example 5. Essence liquid type
50SFMKUF5 분획물 2.0050SFMKUF5 fraction 2.00
히드록시에틸렌셀룰로오스 (2% 수용액) 12.00 Hydroxyethylene Cellulose (2% aqueous solution) 12.00
크산탄검 (2% 수용액) 2.00Xanthan gum (2% aqueous solution) 2.00
1,3-부틸렌글리콜 6.001,3-butylene glycol 6.00
진한 글리세린 4.00Dark glycerin 4.00
히알루론산나트륨 (1% 수용액) 5.00Sodium hyaluronate (1% aqueous solution) 5.00
정제수
잔량
Remaining amount of purified water
상기 제제들은 본 발명에 따른 두유 발효액 또는 두유 펩타이드 분획물을 이용하는 일 형태를 나타내는 것이며, 본 발명에 따른 두유 발효액 또는 두유 펩타이드 분획물은 당 업계에서 사용되는 다양한 제형으로 사용될 수 있으며, 이 또한 본 발명의 범위에 속한다.
The above formulations represent a form using the soymilk fermentation broth or soymilk peptide fraction according to the present invention, and the soymilk fermentation broth or soymilk peptide fraction according to the present invention may be used in various formulations used in the art, and this is also the scope of the present invention. Belongs to.
<110> YONSEI UNIVERSITY BKBIO.CO.,Ltd. Gachon University of Industry-Academic cooperation Foundation LCS Biotech Co., Ltd. <120> Anti-wrinkle cosmetic composition using Lactobacillus paracasei MK1 and preparation method thereof <130> HPC3939 <160> 1 <170> KopatentIn 2.0 <210> 1 <211> 1284 <212> DNA <213> Lactobacillus paracasei <400> 1 tttggaaaca gatgctaata ccgcatagat ccaacaaccg catggttctt ggctgaaaga 60 tggcgtaagc tatcgctttt ggatggaccc gcggcgtatt agctagttgg tgaggtaatg 120 gctcaccaag gcgatgatac gtagccgaac tgagaggttg atcggccaca ttgggactga 180 gacacggccc aaactcctac gggaggcagc agtagggaat cttccacaat ggacgcaagt 240 ctgatggagc aacgccgcgt gagtgaagaa ggctttcggg tcgtaaaact ctgttgttgg 300 agaagaatgg tcggcagagt aactgttgcc ggcgtgacgg tatccaacca gaaagccacg 360 gctaactacg tgccagcagc cgcggtaata cgtaggtggc aagcgttatc cggatttatt 420 gggcgtaaag cgagcgcagg cggtttttta agtctgatgt gaaagccctc ggcttaaccg 480 aggaagcgca tcggaaactg ggaaacttga gtgcagaaga ggacagtgga actccatgtg 540 tagcggtgaa atgcgtagat atatggaaga acaccagtgg cgaaggcggc tgtctggtct 600 gtaactgacg ctgaggctcg aaagcatggg tagcgaacag gattagatac cctggtagtc 660 catgccgtaa acgatgaatg ctaggtgttg gagggtttcc gcccttcagt gccgcagcta 720 acgcattaag cattccgcct ggggagtacg accgcaaggt tgaaactcaa aggaattgac 780 gggggcccgc acaagcggtg gagcatgtgg tttaattcga agcaacgcga agaaccttac 840 caggtcttga catcttttga tcacctgaga gatcaggttt ccccttcggg ggcaaaatga 900 caggtggtgc atggttgtcg tcagctcgtg tcgtgagatg ttgggttaag tcccgcaacg 960 agcgcaaccc ttatgactag ttgccagcat ttagttgggc actctagtaa gactgccggt 1020 gacaaaccgg aggaaggtgg ggatgacgtc aaatcatcat gccccttatg acctgggcta 1080 cacacgtgct acaatggatg gtacaacgag ttgcgagacc gcgaggtcaa gctaatctct 1140 taaagccatt ctcagttcgg actgtaggct gcaactcgcc tacacgaagt cggaatcgct 1200 agtaatcgcg gatcagcacg ccgcggtgaa tacgttcccg ggccttgtac acaccgcccg 1260 tcacaccatg agagttgtaa cacc 1284 <110> YONSEI UNIVERSITY BKBIO.CO.,Ltd. Gachon University of Industry-Academic cooperation Foundation LCS Biotech Co., Ltd. <120> Anti-wrinkle cosmetic composition using Lactobacillus paracasei MK1 and preparation method thereof <130> HPC3939 <160> 1 <170> KopatentIn 2.0 <210> 1 <211> 1284 <212> DNA <213> Lactobacillus paracasei <400> 1 tttggaaaca gatgctaata ccgcatagat ccaacaaccg catggttctt ggctgaaaga 60 tggcgtaagc tatcgctttt ggatggaccc gcggcgtatt agctagttgg tgaggtaatg 120 gctcaccaag gcgatgatac gtagccgaac tgagaggttg atcggccaca ttgggactga 180 gacacggccc aaactcctac gggaggcagc agtagggaat cttccacaat ggacgcaagt 240 ctgatggagc aacgccgcgt gagtgaagaa ggctttcggg tcgtaaaact ctgttgttgg 300 agaagaatgg tcggcagagt aactgttgcc ggcgtgacgg tatccaacca gaaagccacg 360 gctaactacg tgccagcagc cgcggtaata cgtaggtggc aagcgttatc cggatttatt 420 gggcgtaaag cgagcgcagg cggtttttta agtctgatgt gaaagccctc ggcttaaccg 480 aggaagcgca tcggaaactg ggaaacttga gtgcagaaga ggacagtgga actccatgtg 540 tagcggtgaa atgcgtagat atatggaaga acaccagtgg cgaaggcggc tgtctggtct 600 gtaactgacg ctgaggctcg aaagcatggg tagcgaacag gattagatac cctggtagtc 660 catgccgtaa acgatgaatg ctaggtgttg gagggtttcc gcccttcagt gccgcagcta 720 acgcattaag cattccgcct ggggagtacg accgcaaggt tgaaactcaa aggaattgac 780 gggggcccgc acaagcggtg gagcatgtgg tttaattcga agcaacgcga agaaccttac 840 caggtcttga catcttttga tcacctgaga gatcaggttt ccccttcggg ggcaaaatga 900 caggtggtgc atggttgtcg tcagctcgtg tcgtgagatg ttgggttaag tcccgcaacg 960 agcgcaaccc ttatgactag ttgccagcat ttagttgggc actctagtaa gactgccggt 1020 gacaaaccgg aggaaggtgg ggatgacgtc aaatcatcat gccccttatg acctgggcta 1080 cacacgtgct acaatggatg gtacaacgag ttgcgagacc gcgaggtcaa gctaatctct 1140 taaagccatt ctcagttcgg actgtaggct gcaactcgcc tacacgaagt cggaatcgct 1200 agtaatcgcg gatcagcacg ccgcggtgaa tacgttcccg ggccttgtac acaccgcccg 1260 tcacaccatg agagttgtaa cacc 1284
Claims (10)
The hydrolysates of soymilk hydrolyzate, in which soybean oil was hydrolyzed with proteolytic enzymes, were treated with Lactobacillus A cosmetic composition for improving wrinkles comprising a fermented soybean hydrolyzate obtained by removing a protein or peptide having a molecular weight exceeding 30 kDa in a fermented soybean milk hydrolyzate fermented by inoculation with paracasei MK1 [Deposit number: KFCC11552P].
Soy milk contains lactobacillus paracasei ( Lactobacillus paracasei ) MK1 [Accession No .: KFCC11552P] in a hydrolyzate of soybean milk fermented by hydrolysis of soybean milk fermented with proteolytic enzyme, the hydrolyzate of soybean milk fermented product having a molecular weight of more than 30 kDa removed Lt; RTI ID = 0.0 > wrinkle. ≪ / RTI >
The cosmetic composition according to claim 1 or 2, wherein the proteolytic enzyme is flavozyme.
The cosmetic composition for improving wrinkles according to claim 3, wherein the protein or peptide having a molecular weight of 5 kDa or more is removed from the fermented product of the soybean hydrolyzate or the hydrolyzate of the soybean fermented product.
5. The method according to claim 4, wherein the hydrolyzate of the soybean hydrolyzate or the hydrolyzate of the soybean fermentate has an activity of producing type I procollagen and inhibiting tumor necrosis factor-alpha (TNF-a) Wherein the cosmetic composition does not exhibit toxicity to the skin.
6. The fermented soybean milk hydrolyzate according to claim 5, wherein the hydrolyzate of the soybean hydrolyzate or the hydrolyzate of the fermented soybean milk has a free amino acid content of at least 60 mg and a content of essential amino acids in the free amino acid is at least 50% A cosmetic composition for improvement.
The cosmetic composition for improving wrinkles according to claim 6, wherein the hydrolyzate of the soybean hydrolyzate or the hydrolyzate of the soybean fermentation product contains a peptide having the amino acid sequence of SEQ ID NO: 1.
상기 두유 가수분해물에 락토바실러스 파라카제이(Lactobacillus paracasei) MK1 [기탁번호: KFCC11552P]를 접종하여 발효시키는 두유 가수분해물의 발효물 제조단계; 및
상기 두유 가수분해물의 발효물에서 분자량 10 kDa 초과하는 단백질 또는 펩타이드를 제거하는 단계;를 포함하는 주름개선용 두유 가수분해물의 발효물의 제조방법.
A step of producing a soybean hydrolyzate which hydrolyzes soybean oil into a protease, flavozyme;
Preparing a fermentation product of a soybean hydrolyzate to be fermented by inoculating the soybean hydrolyzate with Lactobacillus paracasei MK1 [Deposit number: KFCC11552P]; And
And removing the protein or peptide having a molecular weight of more than 10 kDa in the fermented product of the soybean hydrolyzate.
상기 두유 발효물을 단백분해효소인 후라보자임(flavourzyme)으로 가수분해하는 두유 발효물의 가수분해물 제조단계; 및
상기 두유 발효물의 가수분해물에서 분자량 10 kDa 초과하는 단백질 또는 펩타이드를 제거하는 단계;를 포함하는 주름개선용 두유 발효물의 가수분해물의 제조방법.
The step of preparing soybean milk fermented by inoculation with Lactobacillus paracasei MK1 (accession number: KFCC11552P) in soy milk;
Preparing a hydrolyzate of soybean milk fermented by hydrolyzing the fermented soybean milk into a protease, flavorzyme; And
And removing the protein or peptide having a molecular weight of more than 10 kDa from the hydrolyzate of the soybean milk fermented product to produce a hydrolyzate of the fermented soybean milk.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150115383A KR101967793B1 (en) | 2015-08-17 | 2015-08-17 | Anti-wrinkle cosmetic composition using Lactobacillus paracasei MK1 and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150115383A KR101967793B1 (en) | 2015-08-17 | 2015-08-17 | Anti-wrinkle cosmetic composition using Lactobacillus paracasei MK1 and preparation method thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130045547A Division KR20140127437A (en) | 2013-04-24 | 2013-04-24 | Anti-wrinkle cosmetic composition using Lactobacillus paracasei MK1 and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150100596A true KR20150100596A (en) | 2015-09-02 |
KR101967793B1 KR101967793B1 (en) | 2019-08-14 |
Family
ID=54242226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150115383A KR101967793B1 (en) | 2015-08-17 | 2015-08-17 | Anti-wrinkle cosmetic composition using Lactobacillus paracasei MK1 and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101967793B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180000830A (en) * | 2016-06-24 | 2018-01-04 | 주식회사 엘지생활건강 | Cosmetic composition fermented and after formulation and manufacturing method by applying curd formation thereof |
KR102011240B1 (en) | 2019-01-31 | 2019-08-14 | 에스케이바이오랜드 주식회사 | Novel Lactobacillus paracasei SKB1192 strain and its products with light protection |
KR102074895B1 (en) * | 2018-11-23 | 2020-02-07 | 전라북도(농업기술원) | Novel lactobacillus paracasei and food using the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006347925A (en) * | 2005-06-14 | 2006-12-28 | Kyoei Kagaku Kogyo Kk | Plant fermentation product and cosmetic containing the same |
KR100898311B1 (en) * | 2008-10-23 | 2009-05-19 | 주식회사 더멋진 바이오텍 | Cosmetic composition containing extract of mixed fermentation with soy bean milk |
KR20100135871A (en) * | 2008-04-02 | 2010-12-27 | 바스프 뷰티 케어 솔루션즈 프랑스 에스에이에스 | Active ingredient that stimulates the proliferation and/or activity of fibroblasts |
-
2015
- 2015-08-17 KR KR1020150115383A patent/KR101967793B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006347925A (en) * | 2005-06-14 | 2006-12-28 | Kyoei Kagaku Kogyo Kk | Plant fermentation product and cosmetic containing the same |
KR20100135871A (en) * | 2008-04-02 | 2010-12-27 | 바스프 뷰티 케어 솔루션즈 프랑스 에스에이에스 | Active ingredient that stimulates the proliferation and/or activity of fibroblasts |
KR100898311B1 (en) * | 2008-10-23 | 2009-05-19 | 주식회사 더멋진 바이오텍 | Cosmetic composition containing extract of mixed fermentation with soy bean milk |
Non-Patent Citations (1)
Title |
---|
GenBank Accession Number KC758966(2013.04.15.) * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180000830A (en) * | 2016-06-24 | 2018-01-04 | 주식회사 엘지생활건강 | Cosmetic composition fermented and after formulation and manufacturing method by applying curd formation thereof |
KR102074895B1 (en) * | 2018-11-23 | 2020-02-07 | 전라북도(농업기술원) | Novel lactobacillus paracasei and food using the same |
KR102011240B1 (en) | 2019-01-31 | 2019-08-14 | 에스케이바이오랜드 주식회사 | Novel Lactobacillus paracasei SKB1192 strain and its products with light protection |
Also Published As
Publication number | Publication date |
---|---|
KR101967793B1 (en) | 2019-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20140127437A (en) | Anti-wrinkle cosmetic composition using Lactobacillus paracasei MK1 and preparation method thereof | |
KR101425716B1 (en) | Novel Strain of Lactobacillus fermentum spp., Cosmetic Composition Using the same and Preparation Method thereof | |
KR102173646B1 (en) | Streptococcus salivarius sbk4 strain isolated from skin and functional cosmetic composition comprising Streptococcus salivarius sbk4 strain | |
US20220142912A1 (en) | Novel sporichthyaceae microorganism and use thereof | |
EP3476932A2 (en) | Novel sporichthyaceae microorganism and use thereof | |
KR101967793B1 (en) | Anti-wrinkle cosmetic composition using Lactobacillus paracasei MK1 and preparation method thereof | |
JP5303186B2 (en) | NOVEL MICROORGANISM AND ITS VARIANTS AND METHOD FOR PRODUCING POLYsaccharideS | |
KR101628756B1 (en) | Novel Lactobacillus pentosus NEO 1 and extracts from ginseng-fermented products using Lactobacillus pentosus NEO 1 and manufacturing method thereof | |
KR101809265B1 (en) | Cosmetic composition for containing nicotinoyl peptide and fermented natural extracts | |
KR101796500B1 (en) | Lactobacillus Pentosus GFC03 and Fermented Whey Manufactured Using Thereof | |
KR102263454B1 (en) | Skin derived novel lactic acid bacteria having effects of enhancing skin barrier and anti-wrinkle and use thereof | |
KR102140139B1 (en) | Skin derived novel lactic acid bacteria and cosmetic composition comprising thereof | |
KR101694500B1 (en) | Cosmetic composition comprising fermented rice root extract and method for preparing thereof | |
KR102606383B1 (en) | Novel Bacillus endophyticus S2-11 strain | |
KR20200015423A (en) | Composition for skin whitening or anti-wrinkle comprising fermented extract of Ambrosia trifida and Annual fleabane | |
KR102389749B1 (en) | Skin derived novel Lactobacillus fermentum subsp. shebah-101 strain having effects of enhancing skin barrier and anti-wrinkle and use thereof | |
KR102389753B1 (en) | Skin derived novel Lactobacillus plantarum subsp. shebah-202 strain having effects of enhancing skin barrier and anti-wrinkle and use thereof | |
KR101140572B1 (en) | The beneficial effects of the fermented, nano-fractionated aged black gallic for the proliferation of keratinocytes, skin whitening and the prevention of wrinkles | |
KR20230121661A (en) | Composition for skin protection comprising Lactobacillus strain mixture as an active ingredient | |
KR102075103B1 (en) | Cosmetic composition containing the fermented extract of okamejei kenojei | |
KR102039883B1 (en) | Cosmetic composition comprising fermented coconut sugar extract and manufacturing method thereof | |
KR102037039B1 (en) | Composition comprising flocculin for improving skin condition | |
WO2021033726A1 (en) | Conversion method, conversion agent, method for producing royal jelly composition, and lactobacillus bacteria | |
KR102260080B1 (en) | Compositions containing defatted microalgae extract | |
KR102699167B1 (en) | Oat sprout postbiotic composition having skin whitening and wrinkle improvement activity and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |